{ "version": "2.2", "instance": { "nby20251231_10k.htm": { "nsprefix": "nby", "nsuri": "http://www.novabaypharma.com/20251231", "dts": { "schema": { "local": [ "nby-20251231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/currency/2025/currency-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd", "https://xbrl.sec.gov/exch/2025/exch-2025.xsd", "https://xbrl.sec.gov/naics/2025/naics-2025.xsd", "https://xbrl.sec.gov/sic/2025/sic-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "calculationLink": { "local": [ "nby-20251231_cal.xml" ] }, "definitionLink": { "local": [ "nby-20251231_def.xml" ] }, "labelLink": { "local": [ "nby-20251231_lab.xml" ] }, "presentationLink": { "local": [ "nby-20251231_pre.xml" ] }, "inline": { "local": [ "nby20251231_10k.htm" ] } }, "keyStandard": 365, "keyCustom": 97, "axisStandard": 33, "axisCustom": 0, "memberStandard": 45, "memberCustom": 96, "hidden": { "total": 34, "http://xbrl.sec.gov/cyd/2025": 4, "http://fasb.org/us-gaap/2025": 21, "http://xbrl.sec.gov/dei/2025": 5, "http://xbrl.sec.gov/ecd/2025": 4 }, "contextCount": 539, "entityCount": 1, "segmentCount": 145, "elementCount": 762, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2025": 1094, "http://xbrl.sec.gov/dei/2025": 37, "http://xbrl.sec.gov/cyd/2025": 17, "http://xbrl.sec.gov/ecd/2025": 8 }, "report": { "R1": { "role": "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets", "longName": "001 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets-parentheticals", "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)", "shortName": "Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations", "longName": "003 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "longName": "004 - Statement - Consolidated Statements of Stockholders' (Deficit) Equity", "shortName": "Consolidated Statements of Stockholders' (Deficit) Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "i_2023-12-31_StatementEquityComponentsAxis-PreferredStockMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_StatementEquityComponentsAxis-PreferredStockMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity-parentheticals", "longName": "005 - Statement - Consolidated Statements of Stockholders' (Deficit) Equity (Parentheticals)", "shortName": "Consolidated Statements of Stockholders' (Deficit) Equity (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "unique": true } }, "R7": { "role": "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows", "longName": "006 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "nby:LossIncomeFromDiscontinuedOperationsNetOfTaxAttributableToParent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "unique": true } }, "R8": { "role": "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flowsA866F64D-8A89-45C0-926D-49809D27BFD0", "longName": "007 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:InterestPaidNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:InterestPaidNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows4D8E0948-3376-4886-A031-7AF56055462E", "longName": "008 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ConversionOfStockAmountConverted1", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ConversionOfStockAmountConverted1", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R10": { "role": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "longName": "995443 - Disclosure - Award Timing Disclosure", "shortName": "Award Timing Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "ecd:AwardTmgHowMnpiCnsdrdTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "ecd:AwardTmgHowMnpiCnsdrdTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R11": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R12": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 - Disclosure - Insider Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R13": { "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure", "shortName": "Cybersecurity Risk Management and Strategy Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-1-organization", "longName": "995550 - Disclosure - Note 1 - Organization", "shortName": "Note 1 - Organization", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies", "longName": "995551 - Disclosure - Note 2 - Summary of Significant Accounting Policies", "shortName": "Note 2 - Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "longName": "995552 - Disclosure - Note 3 - Fair Value Measurements", "shortName": "Note 3 - Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-4-prepaid-expenses-and-other-current-assets", "longName": "995553 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets", "shortName": "Note 4 - Prepaid Expenses and Other Current Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "nby:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "nby:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-5-accrued-liabilities", "longName": "995554 - Disclosure - Note 5 - Accrued Liabilities", "shortName": "Note 5 - Accrued Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies", "longName": "995555 - Disclosure - Note 6 - Commitments and Contingencies", "shortName": "Note 6 - Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "longName": "995556 - Disclosure - Note 7 - Financing Activities", "shortName": "Note 7 - Financing Activities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes", "longName": "995557 - Disclosure - Note 8 - Convertible Notes", "shortName": "Note 8 - Convertible Notes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "longName": "995558 - Disclosure - Note 9 - Common Stock Warrants and Warrant Liabilities", "shortName": "Note 9 - Common Stock Warrants and Warrant Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "nby:StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "nby:StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit", "longName": "995559 - Disclosure - Note 10 - Stockholders' Deficit", "shortName": "Note 10 - Stockholders' Deficit", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "longName": "995560 - Disclosure - Note 11 - Stock-based Compensation", "shortName": "Note 11 - Stock-based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-12-employee-benefit-plan", "longName": "995561 - Disclosure - Note 12 - Employee Benefit Plan", "shortName": "Note 12 - Employee Benefit Plan", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan", "longName": "995562 - Disclosure - Note 13 - Avenova Asset Divestiture and Bridge Loan", "shortName": "Note 13 - Avenova Asset Divestiture and Bridge Loan", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis-AvenovaAssetsMember", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true }, "uniqueAnchor": null }, "R27": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture", "longName": "995563 - Disclosure - Note 14 - Phaseone Divestiture", "shortName": "Note 14 - Phaseone Divestiture", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis-WoundCareMember", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis-WoundCareMember", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture", "longName": "995564 - Disclosure - Note 15 - Dermadoctor Divestiture", "shortName": "Note 15 - Dermadoctor Divestiture", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis-DermadoctorMember", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true }, "uniqueAnchor": null }, "R29": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations", "longName": "995565 - Disclosure - Note 16 - Summary of Discontinued Operations", "shortName": "Note 16 - Summary of Discontinued Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis-SummaryOfDisposalGroupsMember", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis-SummaryOfDisposalGroupsMember", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes", "longName": "995566 - Disclosure - Note 17 - Income Taxes", "shortName": "Note 17 - Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-18-related-party-transactions", "longName": "995567 - Disclosure - Note 18 - Related Party Transactions", "shortName": "Note 18 - Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "longName": "995568 - Disclosure - Note 19 - Subsequent Events", "shortName": "Note 19 - Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "32", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.novabaypharma.com/20251231/role/statement-significant-accounting-policies-policies", "longName": "995569 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "33", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "longName": "995570 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)", "shortName": "Note 2 - Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "nby:ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "nby:ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-tables", "longName": "995571 - Disclosure - Note 3 - Fair Value Measurements (Tables)", "shortName": "Note 3 - Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables", "longName": "995572 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets (Tables)", "shortName": "Note 4 - Prepaid Expenses and Other Current Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "nby:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "nby:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-5-accrued-liabilities-tables", "longName": "995573 - Disclosure - Note 5 - Accrued Liabilities (Tables)", "shortName": "Note 5 - Accrued Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-tables", "longName": "995574 - Disclosure - Note 6 - Commitments and Contingencies (Tables)", "shortName": "Note 6 - Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-tables", "longName": "995575 - Disclosure - Note 9 - Common Stock Warrants and Warrant Liabilities (Tables)", "shortName": "Note 9 - Common Stock Warrants and Warrant Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "nby:StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "nby:StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-tables", "longName": "995576 - Disclosure - Note 11 - Stock-based Compensation (Tables)", "shortName": "Note 11 - Stock-based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-tables", "longName": "995577 - Disclosure - Note 13 - Avenova Asset Divestiture and Bridge Loan (Tables)", "shortName": "Note 13 - Avenova Asset Divestiture and Bridge Loan (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis-AvenovaAssetsMember", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis-AvenovaAssetsMember", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-tables", "longName": "995578 - Disclosure - Note 14 - Phaseone Divestiture (Tables)", "shortName": "Note 14 - Phaseone Divestiture (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis-WoundCareMember", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis-WoundCareMember", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-tables", "longName": "995579 - Disclosure - Note 15 - Dermadoctor Divestiture (Tables)", "shortName": "Note 15 - Dermadoctor Divestiture (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis-DermadoctorMember", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis-DermadoctorMember", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations-tables", "longName": "995580 - Disclosure - Note 16 - Summary of Discontinued Operations (Tables)", "shortName": "Note 16 - Summary of Discontinued Operations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis-SummaryOfDisposalGroupsMember", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis-SummaryOfDisposalGroupsMember", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-tables", "longName": "995581 - Disclosure - Note 17 - Income Taxes (Tables)", "shortName": "Note 17 - Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-1-organization-details-textual", "longName": "995582 - Disclosure - Note 1 - Organization (Details Textual)", "shortName": "Note 1 - Organization (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2026-01-31_2026-01-31_SubsequentEventTypeAxis-SubsequentEventMember", "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "unique": true } }, "R47": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "longName": "995583 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)", "shortName": "Note 2 - Summary of Significant Accounting Policies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:TangibleAssetImpairmentCharges", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "unique": true } }, "R48": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-cash-cash-equivalents-restricted-cash-and-restricted-cash-equivalents-details", "longName": "995584 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents (Details)", "shortName": "Note 2 - Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "i_2025-12-31", "name": "nby:CashAndCashEquivalentsIncludingDisposalGroup", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "nby:ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31", "name": "nby:CashAndCashEquivalentsIncludingDisposalGroup", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "nby:ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-earnings-per-share-basic-and-diluted-details", "longName": "995585 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Schedule of Earnings Per Share, Basic and Diluted (Details)", "shortName": "Note 2 - Summary of Significant Accounting Policies - Schedule of Earnings Per Share, Basic and Diluted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:IncomeLossFromContinuingOperations", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "nby:IncomeLossFromContinuingOperationsToCommonStockholdersBasic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "unique": true } }, "R50": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details", "longName": "995586 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "shortName": "Note 2 - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details", "longName": "995587 - Disclosure - Note 3 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)", "shortName": "Note 3 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember", "name": "nby:RestrictedCashHeldAsACertificateOfDepositFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember", "name": "nby:RestrictedCashHeldAsACertificateOfDepositFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "longName": "995588 - Disclosure - Note 3 - Fair Value Measurements - Fair Value Valuation Assumptions (Details)", "shortName": "Note 3 - Fair Value Measurements - Fair Value Valuation Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:FairValueAdjustmentOfWarrants", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31_FairValueByLiabilityClassAxis-UnsecuredConvertibleNotesMember_StatementScenarioAxis-StockholderApprovalMay282024Member", "name": "us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "unique": true } }, "R53": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details", "longName": "995589 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)", "shortName": "Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:PrepaidInsurance", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nby:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:PrepaidInsurance", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nby:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-5-accrued-liabilities-summary-of-accrued-liabilities-details", "longName": "995590 - Disclosure - Note 5 - Accrued Liabilities - Summary of Accrued Liabilities (Details)", "shortName": "Note 5 - Accrued Liabilities - Summary of Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:TaxesPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:TaxesPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-details-textual", "longName": "995591 - Disclosure - Note 6 - Commitments and Contingencies (Details Textual)", "shortName": "Note 6 - Commitments and Contingencies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:OperatingLeaseImpairmentLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31_LeaseContractualTermAxis-OfficeSpaceForCorporateHeadquartersInEmeryvilleCaliforniaMember", "name": "us-gaap:OperatingLeaseImpairmentLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "unique": true } }, "R56": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-lease-expense-details", "longName": "995592 - Disclosure - Note 6 - Commitments and Contingencies - Lease Expense (Details)", "shortName": "Note 6 - Commitments and Contingencies - Lease Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-schedule-of-future-lease-payments-details", "longName": "995593 - Disclosure - Note 6 - Commitments and Contingencies - Schedule of Future Lease Payments (Details)", "shortName": "Note 6 - Commitments and Contingencies - Schedule of Future Lease Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual", "longName": "995594 - Disclosure - Note 7 - Financing Activities (Details Textual)", "shortName": "Note 7 - Financing Activities (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "nby:StockIssuedInConnectionWithExerciseOfWarrantsValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30_DebtInstrumentAxis-The2024WarrantRepriceTransactionMember", "name": "us-gaap:DeferredFinanceCostsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "unique": true } }, "R59": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual", "longName": "995595 - Disclosure - Note 8 - Convertible Notes (Details Textual)", "shortName": "Note 8 - Convertible Notes (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-03-24_DebtInstrumentAxis-UnsecuredConvertibleNotesMember", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "unique": true } }, "R60": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual", "longName": "995596 - Disclosure - Note 9 - Common Stock Warrants and Warrant Liabilities (Details Textual)", "shortName": "Note 9 - Common Stock Warrants and Warrant Liabilities (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ProceedsFromWarrantExercises", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "nby:StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-07-26_ClassOfWarrantOrRightAxis-TheJuly2024SeriesF1WarrantsMember", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "tbody", "table", "nby:StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "unique": true } }, "R61": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details", "longName": "995597 - Disclosure - Note 9 - Common Stock Warrants and Warrant Liabilities - Schedule of Stockholders' Equity Note, Warrants or Rights (Details)", "shortName": "Note 9 - Common Stock Warrants and Warrant Liabilities - Schedule of Stockholders' Equity Note, Warrants or Rights (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nby:StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nby:StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "unique": true } }, "R62": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details", "longName": "995598 - Disclosure - Note 9 - Common Stock Warrants and Warrant Liabilities (Details)", "shortName": "Note 9 - Common Stock Warrants and Warrant Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:FairValueAdjustmentOfWarrants", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31_FairValueByLiabilityClassAxis-WarrantLiabilityMember", "name": "us-gaap:WarrantsAndRightsOutstanding", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nby:StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "unique": true } }, "R63": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual", "longName": "995599 - Disclosure - Note 10 - Stockholders' Deficit (Details Textual)", "shortName": "Note 10 - Stockholders' Deficit (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2025-08-19", "name": "nby:VotingEquivalent", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "unique": true } }, "R64": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual", "longName": "995600 - Disclosure - Note 11 - Stock-based Compensation (Details Textual)", "shortName": "Note 11 - Stock-based Compensation (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "unique": true } }, "R65": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-options-outstanding-details", "longName": "995601 - Disclosure - Note 11 - Stock-based Compensation - Stock Options Outstanding (Details)", "shortName": "Note 11 - Stock-based Compensation - Stock Options Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "nby:ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "unique": true } }, "R66": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-12-employee-benefit-plan-details-textual", "longName": "995602 - Disclosure - Note 12 - Employee Benefit Plan (Details Textual)", "shortName": "Note 12 - Employee Benefit Plan (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31_RetirementPlanNameAxis-The401kPlanContributionLevelOneMember", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31_RetirementPlanNameAxis-The401kPlanContributionLevelOneMember", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-details-textual", "longName": "995603 - Disclosure - Note 13 - Avenova Asset Divestiture and Bridge Loan (Details Textual)", "shortName": "Note 13 - Avenova Asset Divestiture and Bridge Loan (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:OtherNonoperatingIncomeExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-11-05_LongtermDebtTypeAxis-BridgeLoanMember", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "unique": true } }, "R68": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "longName": "995604 - Disclosure - Note 13 - Avenova Asset Divestiture and Bridge Loan - Discontinued Operations (Details)", "shortName": "Note 13 - Avenova Asset Divestiture and Bridge Loan - Discontinued Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31_DisposalGroupClassificationAxis-DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis-AvenovaAssetsMember", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "unique": true } }, "R69": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-details-textual", "longName": "995605 - Disclosure - Note 14 - Phaseone Divestiture (Details Textual)", "shortName": "Note 14 - Phaseone Divestiture (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "d_2025-01-03_2025-01-03_DisposalGroupClassificationAxis-DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis-WoundCareMember", "name": "us-gaap:ProceedsFromSaleOfIntangibleAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-03_2025-01-03_DisposalGroupClassificationAxis-DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis-WoundCareMember", "name": "us-gaap:ProceedsFromSaleOfIntangibleAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details", "longName": "995606 - Disclosure - Note 14 - Phaseone Divestiture - Held-for-sale (Details)", "shortName": "Note 14 - Phaseone Divestiture - Held-for-sale (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31_DisposalGroupClassificationAxis-DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis-WoundCareMember", "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "unique": true } }, "R71": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-details-textual", "longName": "995607 - Disclosure - Note 15 - Dermadoctor Divestiture (Details Textual)", "shortName": "Note 15 - Dermadoctor Divestiture (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31_RestatementAxis-ScenarioPreviouslyReportedMember", "name": "us-gaap:ProceedsFromDivestitureOfBusinesses", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31_RestatementAxis-ScenarioPreviouslyReportedMember", "name": "us-gaap:ProceedsFromDivestitureOfBusinesses", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details", "longName": "995608 - Disclosure - Note 15 - Dermadoctor Divestiture - Discontinued Operations (Details)", "shortName": "Note 15 - Dermadoctor Divestiture - Discontinued Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31_DisposalGroupClassificationAxis-DiscontinuedOperationsDisposedOfBySaleMember_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis-DermadoctorMember", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "unique": true } }, "R73": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations-disposal-groups-including-discontinued-operations-details", "longName": "995609 - Disclosure - Note 16 - Summary of Discontinued Operations - Disposal Groups, Including Discontinued Operations (Details)", "shortName": "Note 16 - Summary of Discontinued Operations - Disposal Groups, Including Discontinued Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "unique": true } }, "R74": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-details-textual", "longName": "995610 - Disclosure - Note 17 - Income Taxes (Details Textual)", "shortName": "Note 17 - Income Taxes (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "unique": true } }, "R75": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-loss-before-provision-for-income-taxes-details", "longName": "995611 - Disclosure - Note 17 - Income Taxes - Loss Before Provision for Income Taxes (Details)", "shortName": "Note 17 - Income Taxes - Loss Before Provision for Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-federal-and-state-income-tax-provisions-details", "longName": "995612 - Disclosure - Note 17 - Income Taxes - Federal and State Income Tax Provisions (Details)", "shortName": "Note 17 - Income Taxes - Federal and State Income Tax Provisions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details", "longName": "995613 - Disclosure - Note 17 - Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details)", "shortName": "Note 17 - Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-net-operating-loss-and-tax-credit-carryforwards-details", "longName": "995614 - Disclosure - Note 17 - Income Taxes - Summary of Net operating Loss and Tax Credit Carryforwards (Details)", "shortName": "Note 17 - Income Taxes - Summary of Net operating Loss and Tax Credit Carryforwards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "i_2025-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember", "name": "us-gaap:TaxCreditCarryforwardAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "nby:SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember", "name": "us-gaap:TaxCreditCarryforwardAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "nby:SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R79": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-unrecognized-tax-benefit-details", "longName": "995615 - Disclosure - Note 17 - Income Taxes - Unrecognized Tax Benefit (Details)", "shortName": "Note 17 - Income Taxes - Unrecognized Tax Benefit (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "unique": true } }, "R80": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details", "longName": "995616 - Disclosure - Note 17 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)", "shortName": "Note 17 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R81": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-income-tax-paid-net-of-refunds-details", "longName": "995617 - Disclosure - Note 17 - Income Taxes - Schedule of Income Tax Paid, Net of Refunds (Details)", "shortName": "Note 17 - Income Taxes - Schedule of Income Tax Paid, Net of Refunds (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "nby:ScheduleOfIncomeTaxPaidNetOfRefundsTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "nby:ScheduleOfIncomeTaxPaidNetOfRefundsTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R82": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-18-related-party-transactions-details-textual", "longName": "995618 - Disclosure - Note 18 - Related Party Transactions (Details Textual)", "shortName": "Note 18 - Related Party Transactions (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "i_2025-12-31", "name": "nby:MonthlyConsultingFee", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31", "name": "nby:MonthlyConsultingFee", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true, "unique": true } }, "R83": { "role": "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "longName": "995619 - Disclosure - Note 19 - Subsequent Events (Details Textual)", "shortName": "Note 19 - Subsequent Events (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2026-03-16_CryptoAssetAxis-SKYTokensMember_StatementScenarioAxis-ScenarioForecastMember", "name": "us-gaap:CryptoAssetFairValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nby20251231_10k.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountingPoliciesAbstract", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-5-accrued-liabilities" ], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r71", "r73", "r78", "r1223" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r71", "r940" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets", "http://www.novabaypharma.com/20251231/role/statement-note-5-accrued-liabilities-summary-of-accrued-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Total accrued liabilities", "label": "Accrued liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r73" ] }, "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows4D8E0948-3376-4886-A031-7AF56055462E" ], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of non-cash information:" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r87", "r940", "r1317" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r742", "r1083", "r1084", "r1085", "r1088", "r1242", "r1319" ] }, "nby_AdjustmentToWarrantExercisePriceDeemedDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "AdjustmentToWarrantExercisePriceDeemedDividend", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_AdjustmentToWarrantExercisePriceDeemedDividend", "terseLabel": "Adjustment to Warrant Exercise Price, Deemed Dividend", "documentation": "The amount of deemed dividend from the adjustments to warrant exercise price." } } }, "auth_ref": [] }, "nby_AdjustmentsToAdditionalPaidInCapitalDeemedCapitalContribution": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "AdjustmentsToAdditionalPaidInCapitalDeemedCapitalContribution", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows4D8E0948-3376-4886-A031-7AF56055462E", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Deemed Capital Contribution pursuant to Series F Agreements", "terseLabel": "Deemed Capital Contribution pursuant to Series F Agreements", "documentation": "Amount of adjustment to additional paid in capital deemed capital contribution." } } }, "auth_ref": [] }, "nby_AdjustmentsToAdditionalPaidInCapitalDownRoundFeatureAdjustmentRelatedToPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "AdjustmentsToAdditionalPaidInCapitalDownRoundFeatureAdjustmentRelatedToPreferredStock", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity" ], "lang": { "en-us": { "role": { "label": "Adjustment of Preferred Stock conversion price", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from down round feature adjustment related to preferred stock." } } }, "auth_ref": [] }, "nby_AdjustmentsToAdditionalPaidInCapitalModificationOfWarrant": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "AdjustmentsToAdditionalPaidInCapitalModificationOfWarrant", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity" ], "lang": { "en-us": { "role": { "label": "Adjustment to Additional Paid in Capital, Modification of Warrant", "documentation": "Amount of increase to APIC from modification of warrant." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation expense related to employee and director stock awards", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement." } } }, "auth_ref": [ "r1131", "r1194" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity" ], "lang": { "en-us": { "role": { "label": "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "negatedLabel": "Issuance of Preferred Stock", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } }, "auth_ref": [ "r12", "r120" ] }, "nby_AdjustmentsToAdditionalPaidInCapitalWarrantRepurchase": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantRepurchase", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity" ], "lang": { "en-us": { "role": { "label": "nby_AdjustmentsToAdditionalPaidInCapitalWarrantRepurchase", "negatedLabel": "Repurchase of Warrants", "documentation": "Amount of additional paid in capital of warrants repurchased." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "nby_AfterAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "AfterAdjustmentMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "After Adjustment [Member]", "documentation": "Related to after adjustment." } } }, "auth_ref": [] }, "nby_AfterRatchetMarch242024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "AfterRatchetMarch242024Member", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "After Ratchet, March 24, 2024 [Member]", "documentation": "Represents after ratchet on March 24, 2024." } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AllocatedShareBasedCompensationExpense", "terseLabel": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r470", "r479", "r489" ] }, "nby_AmendedJuly2020WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "AmendedJuly2020WarrantsMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "Amended July 2020 Warrants [Member]", "documentation": "Represents amended July 2020 warrants." } } }, "auth_ref": [] }, "nby_AmendedNovember2021WarrantsExercisableFor150Member": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "AmendedNovember2021WarrantsExercisableFor150Member", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "Amended November 2021 Warrants Exercisable for 1.50 [Member]", "documentation": "Represents Amended November 2021 Warrants exercisable for $1.50." } } }, "auth_ref": [] }, "nby_AmendedNovember2021WarrantsExercisableFor650Member": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "AmendedNovember2021WarrantsExercisableFor650Member", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "Amended November 2021 Warrants Exercisable for 6.50 [Member]", "documentation": "Represents the Amended November 2021 Warrants exercisable for $6.50." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Amortization of debt discounts on convertible notes", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": [ "r8", "r97", "r339", "r1267" ] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AmortizationOfFinancingCostsAndDiscounts", "negatedLabel": "Accretion of interest and amortization of discounts on convertible notes", "terseLabel": "Amortization of Debt Issuance Costs and Discounts", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r339", "r871", "r872", "r1072", "r1267" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "Anti-dilutive securities (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r241" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r241" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r241" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_Assets", "totalLabel": "TOTAL ASSETS", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r128", "r138", "r169", "r199", "r201", "r202", "r244", "r252", "r261", "r262", "r270", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r550", "r552", "r634", "r686", "r687", "r693", "r778", "r862", "r863", "r873", "r940", "r945", "r946", "r958", "r1126", "r1127", "r1275" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsAbstract", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r165", "r174", "r199", "r201", "r202", "r270", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r550", "r552", "r634", "r940", "r1126", "r1127", "r1275" ] }, "nby_AssetsHeldForSalePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "AssetsHeldForSalePolicyTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Assets Held For Sale [Policy Text Block]", "documentation": "The accounting policy disclosure for assets held for sale." } } }, "auth_ref": [] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Total assets, discontinued operations", "label": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r2", "r52", "r66", "r110", "r163", "r164" ] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations-disposal-groups-including-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Total current assets, discontinued operations", "label": "Current assets, discontinued operations", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r2", "r52", "r66", "r108", "r110", "r163", "r164" ] }, "nby_AtTheMarketOfferingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "AtTheMarketOfferingAgreementMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-1-organization", "http://www.novabaypharma.com/20251231/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "At the Market Offering Agreement [Member]", "documentation": "Related to an at the market offering agreement." } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorFirmId", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_AuditorFirmId", "terseLabel": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r962", "r963", "r976" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorLocation", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_AuditorLocation", "terseLabel": "Auditor Location" } } }, "auth_ref": [ "r962", "r963", "r976" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorName", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_AuditorName", "terseLabel": "Auditor Name" } } }, "auth_ref": [ "r962", "r963", "r976" ] }, "nby_AvenovaAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "AvenovaAssetsMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-tables", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations-disposal-groups-including-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "Avenova Assets [Member]", "documentation": "Represents the Avenova Assets." } } }, "auth_ref": [] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r979" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r979" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "ecd_AwardTmgMnpiCnsdrdFlag", "terseLabel": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r979" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AwardTypeAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r441", "r442", "r443", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r465", "r466", "r467", "r468", "r469" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r1073" ] }, "us-gaap_BridgeLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BridgeLoanMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-details-textual" ], "lang": { "en-us": { "role": { "label": "Bridge Loan [Member]", "documentation": "Financing which is expected to be replaced by a medium to long-term loan. The loan \"bridges\" the gap in time when otherwise no financing would be in place." } } }, "auth_ref": [] }, "us-gaap_CaliforniaFranchiseTaxBoardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CaliforniaFranchiseTaxBoardMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-income-tax-paid-net-of-refunds-details" ], "lang": { "en-us": { "role": { "label": "California Franchise Tax Board [Member]", "documentation": "Designated tax department of the government of the state of California." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r24", "r167", "r844" ] }, "nby_CashAndCashEquivalentsIncludingDisposalGroup": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "CashAndCashEquivalentsIncludingDisposalGroup", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-cash-cash-equivalents-restricted-cash-and-restricted-cash-equivalents-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents", "label": "nby_CashAndCashEquivalentsIncludingDisposalGroup", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r25" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-cash-cash-equivalents-restricted-cash-and-restricted-cash-equivalents-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Total cash, cash equivalents, and restricted cash in the Consolidated Statements of Cash Flows", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of year", "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r24", "r103", "r196" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations", "periodEndLabel": "Cash, cash equivalents and restricted cash of continuing operations, end of year", "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r24", "r103", "r196" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net decrease in cash, cash equivalents and restricted cash, consolidated", "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r1", "r103" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations", "totalLabel": "Net decrease in cash, cash equivalents, and restricted cash, continuing operations", "documentation": "Amount of increase (decrease) in cash, cash equivalent, and cash and cash equivalent restricted to withdrawal or usage, including effect from exchange rate change; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r1070", "r1264" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectDisposalGroupIncludingDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectDisposalGroupIncludingDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Net increase in cash and cash equivalents, discontinued operations", "documentation": "Amount of increase (decrease) in cash, cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change; attributable to discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r1070", "r1264" ] }, "us-gaap_CashDivestedFromDeconsolidation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashDivestedFromDeconsolidation", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashDivestedFromDeconsolidation", "negatedTerseLabel": "Cash transferred to New Age Investments, LLC", "documentation": "Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash." } } }, "auth_ref": [ "r100" ] }, "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Net cash provided by investing activities, discontinued operations", "label": "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "terseLabel": "Net cash provided by investing activities, discontinued operations", "documentation": "Amount of cash inflow (outflow) from investing activity attributable to discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets." } } }, "auth_ref": [ "r65", "r103" ] }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Net cash (used in) provided by operating activities, discontinued operations", "label": "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "terseLabel": "Net cash used in operating activities, discontinued operations", "documentation": "Amount of cash inflow (outflow) from operating activity attributable to discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity." } } }, "auth_ref": [ "r65", "r103" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_CityAreaCode", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfStockDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets", "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows4D8E0948-3376-4886-A031-7AF56055462E", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r145", "r170", "r171", "r172", "r199", "r202", "r234", "r235", "r238", "r240", "r246", "r247", "r270", "r308", "r310", "r311", "r312", "r315", "r316", "r350", "r351", "r353", "r354", "r356", "r360", "r363", "r364", "r368", "r371", "r378", "r634", "r733", "r734", "r735", "r736", "r742", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r766", "r786", "r808", "r825", "r826", "r827", "r828", "r829", "r997", "r1076", "r1078", "r1089" ] }, "nby_ClassOfWarrantOrRightAdditionalRepurchase": { "xbrltype": "sharesItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ClassOfWarrantOrRightAdditionalRepurchase", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_ClassOfWarrantOrRightAdditionalRepurchase", "terseLabel": "Class of Warrant or Right, Additional Repurchase (in shares)", "documentation": "Additional shares of warrants or rights repurchased during the period." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r1132" ] }, "nby_ClassOfWarrantOrRightCancelledDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ClassOfWarrantOrRightCancelledDuringPeriod", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_ClassOfWarrantOrRightCancelledDuringPeriod", "terseLabel": "Class of Warrant or Right, Cancelled During Period", "documentation": "The number of warrants or rights which were cancelled during period." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "nby_ClassOfWarrantOrRightExchangedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ClassOfWarrantOrRightExchangedDuringPeriod", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details" ], "lang": { "en-us": { "role": { "label": "Warrants exchanged pursuant to Series F Agreements (in shares)", "documentation": "The number of warrants or rights exchanged during the period." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r199", "r205", "r379" ] }, "nby_ClassOfWarrantOrRightExercisePricePercentageOfVolumeWeightedAveragePrices": { "xbrltype": "percentItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ClassOfWarrantOrRightExercisePricePercentageOfVolumeWeightedAveragePrices", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_ClassOfWarrantOrRightExercisePricePercentageOfVolumeWeightedAveragePrices", "terseLabel": "Class of Warrant or Right, Exercise Price, Percentage of Volume Weighted Average Prices", "documentation": "Percentage of volume weighted average prices for exercise price of warrant or right." } } }, "auth_ref": [] }, "nby_ClassOfWarrantOrRightExercisePriceTradingDays": { "xbrltype": "durationItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ClassOfWarrantOrRightExercisePriceTradingDays", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_ClassOfWarrantOrRightExercisePriceTradingDays", "terseLabel": "Class of Warrant or Right, Exercise Price, Trading Days", "documentation": "The number of trading days for calculation of exercise price of warrant or right." } } }, "auth_ref": [] }, "nby_ClassOfWarrantOrRightExercisedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ClassOfWarrantOrRightExercisedDuringPeriod", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details" ], "lang": { "en-us": { "role": { "label": "Warrants exercised (in shares)", "terseLabel": "Class of Warrant or Right, Exercised During Period (in shares)", "documentation": "The number of warrants or rights exercised during period." } } }, "auth_ref": [] }, "nby_ClassOfWarrantOrRightExpiredDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ClassOfWarrantOrRightExpiredDuringPeriod", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details" ], "lang": { "en-us": { "role": { "label": "nby_ClassOfWarrantOrRightExpiredDuringPeriod", "negatedLabel": "Warrants expired (in shares)", "documentation": "The number of warrants or rights which expired unexercised during period." } } }, "auth_ref": [] }, "nby_ClassOfWarrantOrRightIssuedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ClassOfWarrantOrRightIssuedDuringPeriod", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details" ], "lang": { "en-us": { "role": { "label": "Warrants granted (in shares)", "terseLabel": "Class of Warrant or Right, Issued During Period (in shares)", "documentation": "The number of warrants or rights issued during period." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r379" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightOutstanding", "periodStartLabel": "Outstanding warrants (in shares)", "periodEndLabel": "Outstanding warrants (in shares)", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "nby_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights": { "xbrltype": "perShareItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights", "terseLabel": "Class of Warrant or Right, Purchase Price of Warrants or Rights", "documentation": "The per share purchase price of warrants or rights." } } }, "auth_ref": [] }, "nby_ClassOfWarrantOrRightRepurchased": { "xbrltype": "sharesItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ClassOfWarrantOrRightRepurchased", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details" ], "lang": { "en-us": { "role": { "label": "Warrants repurchased (in shares)", "terseLabel": "Class of Warrant or Right, Repurchased", "documentation": "The number of warrants or rights repurchased." } } }, "auth_ref": [] }, "nby_ClassOfWarrantOrRightRepurchasedNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ClassOfWarrantOrRightRepurchasedNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_ClassOfWarrantOrRightRepurchasedNumberOfSecuritiesCalledByWarrantsOrRights", "terseLabel": "Class of Warrant or Right Repurchased, Number of Securities Called By Warrants or Rights (in shares)", "documentation": "The number of securities called by warrants or rights repurchased." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-tables" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": [ "r1132" ] }, "nby_ComissionPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ComissionPercent", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_ComissionPercent", "terseLabel": "Comission, Percent", "documentation": "The percentage that the commission will be." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r79", "r132", "r694", "r765" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r113", "r300", "r301", "r835", "r1118", "r1123" ] }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockDividendsPerShareCashPaid", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common Stock, Dividends, Per Share, Cash Paid (in dollars per share)", "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r120" ] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_CommonStockDividendsPerShareDeclared", "terseLabel": "Common Stock, Dividends, Per Share, Declared (in dollars per share)", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r120" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r948", "r949", "r950", "r952", "r953", "r954", "r955", "r1083", "r1084", "r1088", "r1242", "r1316", "r1319" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Common stock, par value (in dollars per share)", "terseLabel": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r85" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized (in shares)", "terseLabel": "Common Stock, Shares Authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r85", "r766" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r85" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r12", "r85", "r766", "r784", "r1319", "r1320" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Common stock, $0.01 par value; 1,500,000 shares authorized, 25,216 and 977 shares issued and outstanding at December 31, 2025 and 2024, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r85", "r351", "r359", "r697", "r940" ] }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ComponentsOfDeferredTaxAssetsAbstract", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Deferred tax assets:" } } }, "auth_ref": [] }, "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Deferred tax liabilities:" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument." } } }, "auth_ref": [ "r632", "r633" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r49", "r854" ] }, "nby_ConversionApprovalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ConversionApprovalMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Conversion Approval [Member]", "documentation": "Represents the Conversion Approval." } } }, "auth_ref": [] }, "nby_ConversionOfSeriesBPreferredStockToCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ConversionOfSeriesBPreferredStockToCommonStockMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Conversion of Series B Preferred Stock to Common Stock [Member]", "documentation": "Represents conversion of series b preferred stock to common stock." } } }, "auth_ref": [] }, "nby_ConversionOfSeriesCPreferredStockToCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ConversionOfSeriesCPreferredStockToCommonStockMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity" ], "lang": { "en-us": { "role": { "label": "Conversion of Series C Preferred Stock to Common Stock [Member]", "documentation": "Represents conversion of series c preferred stock to common stock." } } }, "auth_ref": [] }, "nby_ConversionOfSeriesDPreferredStockIntoCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ConversionOfSeriesDPreferredStockIntoCommonStockMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity" ], "lang": { "en-us": { "role": { "label": "Conversion of Series D Preferred Stock Into Common Stock [Member]", "documentation": "Represents conversion of Series D preferred stock into common stock." } } }, "auth_ref": [] }, "nby_ConversionOfSeriesEPreferredStockIntoCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ConversionOfSeriesEPreferredStockIntoCommonStockMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Conversion of Series E Preferred Stock Into Common Stock [Member]", "documentation": "Represents conversion of Series E preferred stock into common stock." } } }, "auth_ref": [] }, "us-gaap_ConversionOfStockAmountConverted1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConversionOfStockAmountConverted1", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows4D8E0948-3376-4886-A031-7AF56055462E" ], "lang": { "en-us": { "role": { "label": "Conversions of preferred stock to common stock", "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r26", "r27", "r28" ] }, "us-gaap_ConversionOfStockByUniqueDescriptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConversionOfStockByUniqueDescriptionAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Stock Conversion Description [Axis]", "documentation": "Information by description of stock conversions." } } }, "auth_ref": [ "r26", "r27", "r28" ] }, "us-gaap_ConversionOfStockNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConversionOfStockNameDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Conversion of Stock, Name [Domain]", "documentation": "The unique name of a noncash or part noncash stock conversion." } } }, "auth_ref": [ "r26", "r27", "r28" ] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConversionOfStockSharesConverted1", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ConversionOfStockSharesConverted1", "terseLabel": "Conversion of Stock, Shares Converted", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r26", "r27", "r28" ] }, "us-gaap_ConversionOfStockSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConversionOfStockSharesIssued1", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ConversionOfStockSharesIssued1", "terseLabel": "Conversion of Stock, Shares Issued", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r26", "r27", "r28" ] }, "nby_ConversionOfUnsecuredConvertibleNotesToCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ConversionOfUnsecuredConvertibleNotesToCommonStockMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Conversion of Unsecured Convertible Notes To Common Stock [Member]", "documentation": "Represents the conversion of the unsecured convertible debt into common stock." } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConvertibleDebtSecuritiesMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "Convertible Debt Securities [Member]", "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder." } } }, "auth_ref": [ "r1155", "r1183" ] }, "us-gaap_CostOfSalesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CostOfSalesPolicyTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Cost of Goods and Service [Policy Text Block]", "documentation": "Disclosure of accounting policy for cost of product sold and service rendered." } } }, "auth_ref": [ "r1013" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r199", "r208", "r209", "r321", "r366", "r670", "r680", "r692", "r847", "r848", "r849", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1237", "r1238", "r1239", "r1240" ] }, "srt_CryptoAssetAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CryptoAssetAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-1-organization", "http://www.novabaypharma.com/20251231/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Crypto Asset [Axis]" } } }, "auth_ref": [ "r281", "r282", "r283", "r284", "r285", "r293", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113" ] }, "us-gaap_CryptoAssetCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CryptoAssetCost", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_CryptoAssetCost", "terseLabel": "Crypto Asset, Cost", "documentation": "Cost of crypto asset. Excludes crypto asset held for platform user." } } }, "auth_ref": [ "r281", "r283" ] }, "srt_CryptoAssetDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CryptoAssetDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-1-organization", "http://www.novabaypharma.com/20251231/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Crypto Asset [Domain]" } } }, "auth_ref": [ "r281", "r282", "r283", "r284", "r285", "r293", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113" ] }, "us-gaap_CryptoAssetFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CryptoAssetFairValue", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_CryptoAssetFairValue", "terseLabel": "Crypto Asset, Fair Value", "documentation": "Fair value of crypto asset. Excludes crypto asset held for platform user." } } }, "auth_ref": [ "r280", "r281", "r284", "r286" ] }, "us-gaap_CryptoAssetNumberOfUnits": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CryptoAssetNumberOfUnits", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_CryptoAssetNumberOfUnits", "terseLabel": "Crypto Asset, Number of Units", "documentation": "Number of restricted and unrestricted crypto asset units held. Excludes crypto asset units held for platform user." } } }, "auth_ref": [ "r285" ] }, "nby_CryptoAssetNumberOfUnitsAcquired": { "xbrltype": "integerItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "CryptoAssetNumberOfUnitsAcquired", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_CryptoAssetNumberOfUnitsAcquired", "terseLabel": "Crypto Asset, Number of Units, Acquired", "documentation": "Number of restricted and unrestricted crypto asset units acquired." } } }, "auth_ref": [] }, "nby_CryptoAssetNumberOfUnitsSold": { "xbrltype": "integerItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "CryptoAssetNumberOfUnitsSold", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_CryptoAssetNumberOfUnitsSold", "terseLabel": "Crypto Asset, Number of Units, Sold", "documentation": "Number of restricted and unrestricted crypto asset units sold." } } }, "auth_ref": [] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-federal-and-state-income-tax-provisions-details": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-federal-and-state-income-tax-provisions-details" ], "lang": { "en-us": { "role": { "label": "Federal", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1012", "r1074", "r1080", "r1234" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CurrentForeignTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-federal-and-state-income-tax-provisions-details": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-federal-and-state-income-tax-provisions-details" ], "lang": { "en-us": { "role": { "label": "Foreign", "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r1012", "r1074", "r1080" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-federal-and-state-income-tax-provisions-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-federal-and-state-income-tax-provisions-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_CurrentIncomeTaxExpenseBenefit", "totalLabel": "Total current tax expense", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r520", "r1074", "r1080" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-federal-and-state-income-tax-provisions-details" ], "lang": { "en-us": { "role": { "label": "Current" } } }, "auth_ref": [] }, "nby_CurrentOtherTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "CurrentOtherTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-federal-and-state-income-tax-provisions-details": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-federal-and-state-income-tax-provisions-details" ], "lang": { "en-us": { "role": { "label": "Other", "documentation": "Amount of current other tax expense (benefit) attributable to income (loss) from continuing operations." } } }, "auth_ref": [] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-federal-and-state-income-tax-provisions-details": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-federal-and-state-income-tax-provisions-details" ], "lang": { "en-us": { "role": { "label": "State", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1012", "r1074", "r1080", "r1234" ] }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r971", "r990" ] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": [ "r971", "r990" ] }, "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]" } } }, "auth_ref": [ "r973", "r992" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": [ "r973", "r992" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]" } } }, "auth_ref": [ "r975", "r994" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r973", "r992" ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth_ref": [ "r966", "r985" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": [ "r967", "r986" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Text Block]" } } }, "auth_ref": [ "r967", "r986" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": [ "r965", "r984" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]" } } }, "auth_ref": [ "r965", "r984" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]" } } }, "auth_ref": [ "r965", "r984" ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": [ "r968", "r987" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth_ref": [ "r970", "r989" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]" } } }, "auth_ref": [ "r970", "r989" ] }, "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r971", "r990" ] }, "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r974", "r993" ] }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Role of Management [Text Block]" } } }, "auth_ref": [ "r972", "r991" ] }, "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]" } } }, "auth_ref": [ "r969", "r988" ] }, "us-gaap_DebtConversionByUniqueDescriptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtConversionByUniqueDescriptionAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Debt Conversion Description [Axis]", "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction." } } }, "auth_ref": [ "r26", "r28" ] }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtConversionConvertedInstrumentAmount1", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows4D8E0948-3376-4886-A031-7AF56055462E", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Conversion of Unsecured Convertible Notes to common stock", "terseLabel": "Debt Conversion, Converted Instrument, Amount", "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r26", "r28" ] }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtConversionConvertedInstrumentSharesIssued1", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtConversionConvertedInstrumentSharesIssued1", "terseLabel": "Debt Conversion, Converted Instrument, Shares Issued", "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period." } } }, "auth_ref": [ "r26", "r28" ] }, "us-gaap_DebtConversionNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtConversionNameDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Debt Conversion, Name [Domain]", "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r26", "r28" ] }, "us-gaap_DebtConversionOriginalDebtAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtConversionOriginalDebtAmount1", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtConversionOriginalDebtAmount1", "terseLabel": "Debt Conversion, Original Debt, Amount", "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r26", "r28" ] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes" ], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r114", "r199", "r200", "r294", "r295", "r296", "r297", "r298", "r306", "r307", "r317", "r323", "r324", "r325", "r326", "r327", "r328", "r333", "r340", "r341", "r343", "r578", "r642" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r16", "r72", "r73", "r129", "r131", "r318", "r319", "r320", "r321", "r322", "r324", "r329", "r330", "r331", "r332", "r334", "r335", "r336", "r337", "r338", "r339", "r868", "r869", "r870", "r871", "r872", "r930", "r1074", "r1075", "r1077", "r1082", "r1119", "r1120", "r1121", "r1266", "r1268", "r1284" ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentCarryingAmount", "terseLabel": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r16", "r131", "r344" ] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentConvertibleConversionPrice1", "terseLabel": "Debt Instrument, Convertible, Conversion Price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r115", "r320" ] }, "us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal", "terseLabel": "Debt Instrument, Convertible, If-converted Value in Excess of Principal", "documentation": "The amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only." } } }, "auth_ref": [ "r33" ] }, "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentConvertibleNumberOfEquityInstruments", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments", "terseLabel": "Debt Instrument, Convertible, Number of Equity Instruments", "documentation": "The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity." } } }, "auth_ref": [ "r39", "r76", "r118", "r119", "r320" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentFaceAmount", "terseLabel": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r318", "r642", "r643", "r869", "r870", "r930" ] }, "nby_DebtInstrumentFundedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "DebtInstrumentFundedAmount", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_DebtInstrumentFundedAmount", "terseLabel": "Debt Instrument, Funded Amount", "documentation": "Represents the amount of the funded amount for each tranche." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentIncreaseDecreaseForPeriodNet", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet", "negatedLabel": "Debt Instrument, Increase (Decrease), Net", "documentation": "Net increase or decrease in the carrying amount of the debt instrument for the period." } } }, "auth_ref": [ "r1074", "r1077" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentInterestRateEffectivePercentage", "terseLabel": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r75", "r345", "r642", "r643", "r930" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r75", "r319" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r16", "r318", "r319", "r320", "r321", "r322", "r324", "r329", "r330", "r331", "r332", "r334", "r335", "r336", "r337", "r338", "r339", "r868", "r869", "r870", "r871", "r872", "r930", "r1074", "r1075", "r1077", "r1082", "r1119", "r1120", "r1121", "r1266", "r1268", "r1284" ] }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentRedemptionPricePercentage", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentRedemptionPricePercentage", "terseLabel": "Debt Instrument, Redemption Price, Percentage", "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer." } } }, "auth_ref": [ "r136" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentTable", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r16", "r39", "r42", "r50", "r117", "r119", "r318", "r319", "r320", "r321", "r322", "r324", "r329", "r330", "r331", "r332", "r334", "r335", "r336", "r337", "r338", "r339", "r342", "r578", "r690", "r868", "r869", "r870", "r871", "r872", "r930", "r1074", "r1075", "r1077", "r1082", "r1266", "r1268" ] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentUnamortizedDiscount", "terseLabel": "Debt Instrument, Unamortized Discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r1129", "r1265", "r1266", "r1268" ] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables" ], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-federal-and-state-income-tax-provisions-details": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-federal-and-state-income-tax-provisions-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Federal", "label": "us-gaap_DeferredFederalIncomeTaxExpenseBenefit", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1074", "r1080", "r1233", "r1234" ] }, "us-gaap_DeferredFinanceCostsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredFinanceCostsGross", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredFinanceCostsGross", "terseLabel": "Debt Issuance Costs, Gross", "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r1266", "r1268" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details" ], "lang": { "en-us": { "role": { "label": "Deferred financing costs", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r1129", "r1265", "r1266", "r1268" ] }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredForeignIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-federal-and-state-income-tax-provisions-details": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-federal-and-state-income-tax-provisions-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign", "label": "us-gaap_DeferredForeignIncomeTaxExpenseBenefit", "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r1074", "r1080", "r1233" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-federal-and-state-income-tax-provisions-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-federal-and-state-income-tax-provisions-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredIncomeTaxExpenseBenefit", "totalLabel": "Total deferred tax expense", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r8", "r142", "r1074", "r1080" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-federal-and-state-income-tax-provisions-details" ], "lang": { "en-us": { "role": { "label": "Deferred" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredIncomeTaxLiabilities", "negatedLabel": "Total deferred tax liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r80", "r81", "r130", "r511" ] }, "nby_DeferredOtherIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "DeferredOtherIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-federal-and-state-income-tax-provisions-details": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-federal-and-state-income-tax-provisions-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Other", "label": "nby_DeferredOtherIncomeTaxExpenseBenefit", "documentation": "Amount of deferred other income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-federal-and-state-income-tax-provisions-details": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-federal-and-state-income-tax-provisions-details" ], "lang": { "en-us": { "role": { "verboseLabel": "State", "label": "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1074", "r1080", "r1233", "r1234" ] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsGross", "totalLabel": "Total deferred tax assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r512" ] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "totalLabel": "Net deferred taxes", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r1229" ] }, "nby_DeferredTaxAssetsOperatingLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "DeferredTaxAssetsOperatingLeaseLiabilities", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liabilities", "label": "nby_DeferredTaxAssetsOperatingLeaseLiabilities", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Net operating losses", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r1231" ] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Other deferred tax assets", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r1231" ] }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Property and equipment", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment." } } }, "auth_ref": [ "r1231" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Research and development credits", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards." } } }, "auth_ref": [ "r1231" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Stock options", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r1231" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Accruals", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities." } } }, "auth_ref": [ "r1231" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsValuationAllowance", "negatedLabel": "Valuation allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r513" ] }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxLiabilitiesLeasingArrangements", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxLiabilitiesLeasingArrangements", "negatedLabel": "Operating lease right-of-use assets", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements." } } }, "auth_ref": [ "r1231" ] }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-12-employee-benefit-plan-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount", "terseLabel": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-12-employee-benefit-plan-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent", "terseLabel": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-12-employee-benefit-plan-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "terseLabel": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "documentation": "Percentage employer matches of the employee's percentage contribution matched." } } }, "auth_ref": [] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows4D8E0948-3376-4886-A031-7AF56055462E" ], "lang": { "en-us": { "role": { "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r186", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r755", "r757", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r779", "r780", "r781", "r782", "r796", "r797", "r798", "r799", "r802", "r803", "r804", "r805", "r819", "r820", "r822", "r823", "r846", "r847", "r849", "r921", "r922", "r948", "r950", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1237", "r1238", "r1239", "r1240", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows4D8E0948-3376-4886-A031-7AF56055462E" ], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r186", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r755", "r757", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r779", "r780", "r781", "r782", "r796", "r797", "r798", "r799", "r802", "r803", "r804", "r805", "r819", "r820", "r822", "r823", "r846", "r847", "r849", "r921", "r922", "r948", "r950", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1237", "r1238", "r1239", "r1240", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256" ] }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DerivativeLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Warrant liabilities, at fair value", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r175" ] }, "nby_DerivativeLiabilityIssuedWithNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "DerivativeLiabilityIssuedWithNotes", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows4D8E0948-3376-4886-A031-7AF56055462E" ], "lang": { "en-us": { "role": { "label": "Issuance of derivative liability in conjunction with Unsecured Convertible Notes", "documentation": "Amount of derivative liability issued with notes." } } }, "auth_ref": [] }, "nby_DermadoctorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "DermadoctorMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-tables", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations-disposal-groups-including-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "DERMAdoctor [Member]", "documentation": "Represents DERMAdoctor." } } }, "auth_ref": [] }, "nby_DigitalAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "DigitalAssetsPolicyTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Digital Assets [Policy Text Block]", "documentation": "Disclosure of accounting policy for digital assets." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r437", "r440", "r471", "r472", "r474", "r885" ] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisclosureTextBlockAbstract", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-1-organization", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-12-employee-benefit-plan", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes", "http://www.novabaypharma.com/20251231/role/statement-note-18-related-party-transactions", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-4-prepaid-expenses-and-other-current-assets", "http://www.novabaypharma.com/20251231/role/statement-note-5-accrued-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Net income from discontinued operations before income taxes", "label": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r53", "r54", "r55", "r56", "r57", "r63", "r94", "r1285" ] }, "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "verboseLabel": "(Benefit) Provision for income taxes", "label": "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "terseLabel": "Discontinued Operation, Tax Effect of Discontinued Operation", "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r54", "r55", "r56", "r57", "r63", "r68", "r496", "r528", "r530" ] }, "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DiscontinuedOperationsDisposedOfBySaleMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "Discontinued Operations, Disposed of by Sale [Member]", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, disposed of by sale." } } }, "auth_ref": [ "r5" ] }, "us-gaap_DiscontinuedOperationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DiscontinuedOperationsPolicyTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Discontinued Operations, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation." } } }, "auth_ref": [ "r10", "r19" ] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r163" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations." } } }, "auth_ref": [ "r9", "r15" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts receivable, net", "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r2", "r52", "r66", "r110" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent", "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r2", "r52", "r66", "r108", "r110" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued liabilities", "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent", "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r2", "r52", "r66", "r108", "r110" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Other assets, discontinued operations", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r2", "r3", "r52", "r66", "r110", "r163", "r164" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration", "terseLabel": "Disposal Group, Including Discontinued Operation, Consideration", "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation." } } }, "auth_ref": [] }, "nby_DisposalGroupIncludingDiscontinuedOperationConsiderationMaximumPostclosingAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationMaximumPostclosingAdjustment", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_DisposalGroupIncludingDiscontinuedOperationConsiderationMaximumPostclosingAdjustment", "terseLabel": "Disposal Group, Including Discontinued Operation, Consideration, Maximum Post-closing Adjustment", "documentation": "The maximum amount of post-closing adjustment, either upward or downward, on consideration for disposal group including discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Cost of goods sold", "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r64", "r164" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "General and administrative", "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r64" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Gross profit", "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "documentation": "Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r64", "r164" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventory, net", "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r2", "r52", "r66", "r108", "r110" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Total operating expenses", "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r64" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating loss", "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r64" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations-disposal-groups-including-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Other assets", "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets", "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r2", "r3", "r52", "r66", "r110" ] }, "nby_DisposalGroupIncludingDiscontinuedOperationPercentageSold": { "xbrltype": "percentItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "DisposalGroupIncludingDiscontinuedOperationPercentageSold", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_DisposalGroupIncludingDiscontinuedOperationPercentageSold", "terseLabel": "Disposal Group, Including Discontinued Operation, Percentage Sold", "documentation": "Percentage of business sold for the disposal of assets and liabilities, including discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Prepaid expenses and other current assets", "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r2", "r52", "r66", "r108", "r110" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Property and equipment, net, discontinued operations", "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent", "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r2", "r3", "r52", "r66", "r110" ] }, "nby_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Research and development", "label": "nby_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense", "documentation": "Amount of research and development expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Net sales", "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue", "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r64", "r164" ] }, "nby_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "DisposalGroupIncludingDiscontinuedOperationSellingAndMarketingExpense", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Sales and marketing", "label": "nby_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketingExpense", "documentation": "Amount of selling and marketing expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [] }, "nby_DisposalGroupIncludingDiscontinuedOperationTargetWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "DisposalGroupIncludingDiscontinuedOperationTargetWorkingCapital", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_DisposalGroupIncludingDiscontinuedOperationTargetWorkingCapital", "terseLabel": "Disposal Group, Including Discontinued Operation, Target Working Capital", "documentation": "Amount of target working capital for disposal group including discontinued operation." } } }, "auth_ref": [] }, "nby_DisposalGroupNetWorkingCapitalAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "DisposalGroupNetWorkingCapitalAdjustment", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_DisposalGroupNetWorkingCapitalAdjustment", "terseLabel": "Disposal Group, Net Working Capital Adjustment", "documentation": "Amount of net working capital adjustment for disposal groups." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Gain on divestiture", "label": "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "terseLabel": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "negatedTerseLabel": "Non-cash gain on divestiture", "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations." } } }, "auth_ref": [ "r185", "r289", "r1072", "r1114" ] }, "nby_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNoncash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNoncash", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "nby_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNoncash", "negatedTerseLabel": "Non-cash loss on divestiture", "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a non-cash disposal group. Excludes discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList", "terseLabel": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income that includes gain (loss) recognized on sale or disposal of disposal group. Excludes discontinued operation." } } }, "auth_ref": [ "r290" ] }, "nby_DisposalGroupServiceAndSupportPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "DisposalGroupServiceAndSupportPeriod", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_DisposalGroupServiceAndSupportPeriod", "terseLabel": "Disposal Group, Service and Support Period", "documentation": "Period for services and support of disposal group." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations" ], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r51", "r107" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-tables", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-tables", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-tables", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations-disposal-groups-including-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations-tables" ], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r291", "r292", "r882", "r883" ] }, "srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "DistributionOfAssetsLiabilitiesAndStockholdersEquityTable", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-5-accrued-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-5-accrued-liabilities-summary-of-accrued-liabilities-details", "http://www.novabaypharma.com/20251231/role/statement-note-5-accrued-liabilities-tables" ], "lang": { "en-us": { "role": { "label": "Distribution of Assets, Liabilities and Stockholders' Equity [Table]" } } }, "auth_ref": [ "r686", "r687", "r688", "r689" ] }, "us-gaap_Dividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Dividends", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity" ], "lang": { "en-us": { "role": { "label": "us-gaap_Dividends", "negatedLabel": "Dividend Paid", "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock." } } }, "auth_ref": [ "r6", "r120" ] }, "us-gaap_DividendsPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DividendsPreferredStock", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Deemed dividend", "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)." } } }, "auth_ref": [ "r6", "r120" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAnnualReport", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r962", "r963", "r976" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_DocumentFinStmtErrorCorrectionFlag", "terseLabel": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r962", "r963", "r976", "r978" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_DocumentPeriodEndDate", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentTransitionReport", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r977" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_DocumentType", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DomesticCountryMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-net-operating-loss-and-tax-credit-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Domestic Tax Jurisdiction [Member]", "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction." } } }, "auth_ref": [ "r498" ] }, "nby_DownRoundFeatureAdjustmentsRelatedToCommonStockWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "DownRoundFeatureAdjustmentsRelatedToCommonStockWarrants", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows4D8E0948-3376-4886-A031-7AF56055462E" ], "lang": { "en-us": { "role": { "label": "Down round feature adjustments related to common stock warrants", "documentation": "The amount of down round feature adjustments related to common stock warrants." } } }, "auth_ref": [] }, "nby_DownRoundFeatureAdjustmentsRelatedToPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "DownRoundFeatureAdjustmentsRelatedToPreferredStock", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows4D8E0948-3376-4886-A031-7AF56055462E" ], "lang": { "en-us": { "role": { "label": "Down round feature adjustments related to preferred stock", "documentation": "Represents Down Round Feature Adjustments Related to Preferred Stock." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Basic and diluted net loss per share" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerShareBasic", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "us-gaap_EarningsPerShareBasic", "totalLabel": "Basic (loss) earnings per share attributable to common stockholders (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r156", "r182", "r217", "r218", "r219", "r220", "r222", "r223", "r224", "r226", "r231", "r234", "r238", "r239", "r240", "r243", "r349", "r477", "r540", "r549", "r605", "r606", "r685", "r703", "r855" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r29", "r30", "r242" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "totalLabel": "Total, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r498", "r889" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "US Federal Statutory Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r199", "r204", "r498", "r526", "r889" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Change in valuation allowance, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r502", "r889", "r1074", "r1081", "r1224" ] }, "nby_EffectiveIncomeTaxRateReconciliationExpirationOfTaxAttributes": { "xbrltype": "percentItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "EffectiveIncomeTaxRateReconciliationExpirationOfTaxAttributes", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Expiration of tax attributes", "documentation": "Percentage of effective income tax rate for expiration of tax attributes." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation expense", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement." } } }, "auth_ref": [ "r889", "r1074", "r1081", "r1224", "r1226" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Other, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r889", "r1074", "r1081", "r1224", "r1225" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "State and Local income taxes, net of federal income tax effect, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r501", "r889", "r1074", "r1081", "r1224" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationTable", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-federal-and-state-income-tax-provisions-details", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-loss-before-provision-for-income-taxes-details", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-income-tax-paid-net-of-refunds-details", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-net-operating-loss-and-tax-credit-carryforwards-details", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-tables", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-unrecognized-tax-benefit-details" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation [Table]", "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation." } } }, "auth_ref": [ "r498", "r499", "r889" ] }, "nby_EffectiveIncomeTaxRateReconciliationWarrantAndEquityAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "EffectiveIncomeTaxRateReconciliationWarrantAndEquityAmount", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Warrant/equity expenses, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) relating to warrants and equity." } } }, "auth_ref": [] }, "nby_EffectiveIncomeTaxRateReconciliationWarrantAndEquityExpensesPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "EffectiveIncomeTaxRateReconciliationWarrantAndEquityExpensesPercent", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Warrant/equity expenses, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to warrant and equity expenses." } } }, "auth_ref": [] }, "nby_ElectionOfTheHolderPriorToTheDateOfIssuanceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ElectionOfTheHolderPriorToTheDateOfIssuanceMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Election of the holder prior to the date of issuance [Member]", "documentation": "Represents the election of the holder prior to the date of issuance." } } }, "auth_ref": [] }, "nby_EmbeddedDerivativeFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "EmbeddedDerivativeFairValue", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_EmbeddedDerivativeFairValue", "terseLabel": "Embedded Derivative, Fair Value", "documentation": "Represents the fair value of embedded derivative." } } }, "auth_ref": [] }, "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Total value, embedded", "terseLabel": "Embedded Derivative, Fair Value of Embedded Derivative Liability", "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability." } } }, "auth_ref": [ "r1235", "r1246", "r1247", "r1248" ] }, "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Gain, embedded derivative", "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period." } } }, "auth_ref": [ "r1236", "r1241" ] }, "us-gaap_EmbeddedDerivativeLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmbeddedDerivativeLiabilityMeasurementInput", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement input, embedded derivative", "documentation": "Value of input used to measure embedded derivative liability." } } }, "auth_ref": [ "r610", "r611", "r612" ] }, "us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows4D8E0948-3376-4886-A031-7AF56055462E" ], "lang": { "en-us": { "role": { "label": "Embedded derivatives, amount reclassified to stockholders' equity", "documentation": "The amount of the liability for the conversion option reclassified to stockholders' equity when the embedded option no longer required separation from the host instrument." } } }, "auth_ref": [ "r579" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-5-accrued-liabilities-summary-of-accrued-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Employee payroll and benefits", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r73" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r473" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r473" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [ "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1217", "r1218", "r1219", "r1220", "r1221" ] }, "nby_EmployeeStockOptionsAndRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "EmployeeStockOptionsAndRSUMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "Employee Stock Options and RSUs [Member]", "documentation": "Represents employee stock options and restricted stock units (RSUs)." } } }, "auth_ref": [] }, "nby_EmployeesAndDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "EmployeesAndDirectorsMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Employees and Directors [Member]", "documentation": "Represents information about employees and directors." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityAddressAddressLine1", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityAddressCityOrTown", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityAddressPostalZipCode", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityAddressStateOrProvince", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r960" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityCommonStockSharesOutstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityCurrentReportingStatus", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets", "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows4D8E0948-3376-4886-A031-7AF56055462E", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flowsA866F64D-8A89-45C0-926D-49809D27BFD0", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations", "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information", "http://www.novabaypharma.com/20251231/role/statement-note-1-organization", "http://www.novabaypharma.com/20251231/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-options-outstanding-details", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-tables", "http://www.novabaypharma.com/20251231/role/statement-note-12-employee-benefit-plan", "http://www.novabaypharma.com/20251231/role/statement-note-12-employee-benefit-plan-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-tables", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-tables", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-tables", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations-disposal-groups-including-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations-tables", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-federal-and-state-income-tax-provisions-details", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-loss-before-provision-for-income-taxes-details", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-income-tax-paid-net-of-refunds-details", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-net-operating-loss-and-tax-credit-carryforwards-details", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-tables", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-unrecognized-tax-benefit-details", "http://www.novabaypharma.com/20251231/role/statement-note-18-related-party-transactions", "http://www.novabaypharma.com/20251231/role/statement-note-18-related-party-transactions-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-cash-cash-equivalents-restricted-cash-and-restricted-cash-equivalents-details", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-earnings-per-share-basic-and-diluted-details", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-tables", "http://www.novabaypharma.com/20251231/role/statement-note-4-prepaid-expenses-and-other-current-assets", "http://www.novabaypharma.com/20251231/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details", "http://www.novabaypharma.com/20251231/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables", "http://www.novabaypharma.com/20251231/role/statement-note-5-accrued-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-5-accrued-liabilities-summary-of-accrued-liabilities-details", "http://www.novabaypharma.com/20251231/role/statement-note-5-accrued-liabilities-tables", "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies", "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-lease-expense-details", "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-schedule-of-future-lease-payments-details", "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-tables", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-tables", "http://www.novabaypharma.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r960" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityFileNumber", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFilerCategory", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r960" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityInteractiveDataCurrent", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r995" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityPublicFloat", "terseLabel": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityRegistrantName", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r960" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityShellCompany", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityShellCompany", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r960" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntitySmallBusiness", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r960" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r960" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityVoluntaryFilers", "terseLabel": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityWellKnownSeasonedIssuer", "terseLabel": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r996" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EquityComponentDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r12", "r148", "r155", "r156", "r179", "r180", "r181", "r210", "r211", "r212", "r215", "r224", "r227", "r229", "r245", "r271", "r274", "r288", "r348", "r380", "r477", "r521", "r522", "r536", "r537", "r538", "r541", "r548", "r549", "r582", "r584", "r585", "r586", "r587", "r589", "r590", "r591", "r592", "r593", "r604", "r635", "r636", "r637", "r638", "r639", "r640", "r644", "r646", "r664", "r702", "r716", "r717", "r718", "r742", "r808" ] }, "nby_EquityIssuableMaximumOfferingPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "EquityIssuableMaximumOfferingPrice", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_EquityIssuableMaximumOfferingPrice", "terseLabel": "Equity Issuable, Maximum Offering Price", "documentation": "The maximum offering price of equity issuable." } } }, "auth_ref": [] }, "nby_EquityIssuedDuringPeriodSharesAndWarrantsNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "EquityIssuedDuringPeriodSharesAndWarrantsNewIssues", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock and pre-funded warrants in the 2024 Public Offering, net of issuance cost (in shares)", "documentation": "Number of new stock and warrants issued during the period." } } }, "auth_ref": [] }, "nby_EquityIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "EquityIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock and pre-funded warrants in the 2024 Public Offering, net of issuance cost", "documentation": "Equity impact of the value of new stock and warrants issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [] }, "us-gaap_EscrowDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EscrowDeposit", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EscrowDeposit", "terseLabel": "Escrow Deposit", "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy." } } }, "auth_ref": [ "r127", "r836" ] }, "nby_EscrowMaximumPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "EscrowMaximumPeriod", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_EscrowMaximumPeriod", "terseLabel": "Escrow, Maximum Period", "documentation": "The maximum period funds are to be held in escrow." } } }, "auth_ref": [] }, "nby_ExistingWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ExistingWarrantsMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Existing Warrants [Member]", "documentation": "Related to existing warrants." } } }, "auth_ref": [] }, "nby_ExpirationYear2045Member": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ExpirationYear2045Member", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-net-operating-loss-and-tax-credit-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Expiration Year 2045 [Member]", "documentation": "Represents expiration year 2045." } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0, "order": 2.0 }, "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Non-cash loss (gain) on changes in fair value of warrant liability", "negatedLabel": "Non-cash (loss) gain on changes in fair value of warrant liability", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r8" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-tables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r608", "r609", "r622", "r923" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-tables" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r610", "r611", "r925" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-tables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r1244", "r1245" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r331", "r392", "r393", "r394", "r395", "r396", "r397", "r407", "r408", "r607", "r609", "r610", "r611", "r612", "r621", "r622", "r624", "r631", "r675", "r676", "r677", "r841", "r869", "r870", "r877", "r878", "r879", "r880", "r881", "r923", "r925", "r929" ] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueByLiabilityClassAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r613", "r614", "r615", "r616", "r617", "r618", "r623" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r608", "r609", "r610", "r612", "r923", "r1247", "r1257" ] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements" ], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r610", "r617", "r619", "r620", "r621", "r624", "r625", "r626", "r627", "r628", "r684", "r923", "r926" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r331", "r392", "r397", "r407", "r609", "r622", "r631", "r675", "r841", "r877", "r878", "r879", "r880", "r881", "r923", "r929" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r331", "r392", "r397", "r407", "r409", "r609", "r610", "r622", "r631", "r676", "r841", "r869", "r870", "r877", "r878", "r879", "r880", "r881", "r923", "r929" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r331", "r392", "r393", "r394", "r395", "r396", "r397", "r407", "r408", "r609", "r610", "r611", "r612", "r622", "r631", "r677", "r841", "r869", "r870", "r877", "r878", "r879", "r880", "r881", "r923", "r925", "r929" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": [ "r613", "r614", "r615", "r616", "r617", "r618", "r623" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-tables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r613", "r618", "r623" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r608", "r609", "r610", "r612", "r923", "r1247", "r1257" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r331", "r392", "r393", "r394", "r395", "r396", "r397", "r407", "r408", "r607", "r609", "r610", "r611", "r612", "r621", "r622", "r624", "r631", "r675", "r676", "r677", "r841", "r869", "r870", "r877", "r878", "r879", "r880", "r881", "r923", "r925", "r929" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r923", "r1244", "r1245", "r1246", "r1247", "r1248", "r1257" ] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r1258" ] }, "nby_FairValueOfWarrantsIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "FairValueOfWarrantsIssued", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Fair value of October 2025 Pre-Funded Warrants upon issuance", "documentation": "The fair value of warrants issued during the period." } } }, "auth_ref": [] }, "nby_FloridaDepartmentOfRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "FloridaDepartmentOfRevenueMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Florida Department of Revenue [Member]", "documentation": "Represents the Florida Department of Revenue." } } }, "auth_ref": [] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Non-cash loss on extinguishment of Secured Convertible Note", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r8", "r34", "r35" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r96", "r788" ] }, "us-gaap_GranteeStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GranteeStatusAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Grantee Status [Axis]", "documentation": "Information by status of recipient to whom award is granted." } } }, "auth_ref": [ "r438", "r439", "r441", "r442", "r443", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r465", "r466", "r467", "r468", "r469" ] }, "us-gaap_GranteeStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GranteeStatusDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Grantee Status [Domain]", "documentation": "Status of recipient to whom award is granted." } } }, "auth_ref": [ "r438", "r439", "r441", "r442", "r443", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r465", "r466", "r467", "r468", "r469" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_IcfrAuditorAttestationFlag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r962", "r963", "r976" ] }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 }, "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Impairment of long-lived assets", "terseLabel": "Impairment, Long-Lived Asset, Held-for-Use", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)." } } }, "auth_ref": [ "r8", "r31", "r109", "r184", "r850", "r924" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r112" ] }, "nby_IncentiveStockOptionsISOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "IncentiveStockOptionsISOMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Incentive Stock Options (ISOs) [Member]", "documentation": "Represents incentive stock options (ISOs)." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeLossFromContinuingOperations", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 }, "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-loss-before-provision-for-income-taxes-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-loss-before-provision-for-income-taxes-details", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-earnings-per-share-basic-and-diluted-details" ], "lang": { "en-us": { "role": { "label": "Net loss from continuing operations", "totalLabel": "Net loss from continuing operations", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent." } } }, "auth_ref": [ "r48", "r93", "r105", "r156", "r219", "r220", "r222", "r223", "r224", "r236", "r240", "r549" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-loss-before-provision-for-income-taxes-details": { "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-loss-before-provision-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "United States", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r199", "r203", "r497" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-loss-before-provision-for-income-taxes-details": { "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-loss-before-provision-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "International", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r199", "r203", "r497" ] }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Basic loss per share from continuing operations (in dollars per share)", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r93", "r134", "r156", "r182", "r214", "r217", "r218", "r219", "r220", "r222", "r223", "r224", "r234", "r238", "r239", "r349", "r540", "r549", "r606", "r685", "r1286" ] }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare", "terseLabel": "Income (Loss) from Continuing Operations, Per Diluted Share", "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r93", "r156", "r182", "r214", "r217", "r218", "r219", "r220", "r222", "r223", "r224", "r234", "r238", "r239", "r240", "r549", "r606", "r685", "r1286" ] }, "nby_IncomeLossFromContinuingOperationsToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "IncomeLossFromContinuingOperationsToCommonStockholdersBasic", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-earnings-per-share-basic-and-diluted-details" ], "lang": { "en-us": { "role": { "label": "Net loss from continuing operations attributable to common stockholders", "documentation": "Amount of net income (loss) from continuing operations to common stockholders basic." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations-disposal-groups-including-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-earnings-per-share-basic-and-diluted-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Net income from discontinued operations, net of taxes", "label": "Net income from discontinued operations, net of taxes", "terseLabel": "Net loss from discontinued operations", "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r53", "r54", "r55", "r56", "r57", "r63", "r68", "r125" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Basic earnings per share from discontinued operations (in dollars per share)", "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": [ "r94", "r182", "r235", "r238", "r239", "r1283", "r1286" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-tables", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-tables", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-tables", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations-disposal-groups-including-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations-tables" ], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r291", "r292", "r882", "r883" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-tables", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-tables", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-tables", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations-disposal-groups-including-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations-tables" ], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r10", "r15", "r18", "r52", "r58", "r59", "r60", "r61", "r62", "r67", "r69", "r70", "r111", "r291", "r292" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-net-operating-loss-and-tax-credit-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": [ "r195", "r498", "r499", "r506", "r517", "r889", "r1230" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-net-operating-loss-and-tax-credit-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Domain]", "documentation": "Income tax jurisdiction." } } }, "auth_ref": [ "r195", "r498", "r499", "r506", "r517", "r889", "r1230" ] }, "us-gaap_IncomeTaxAuthorityNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxAuthorityNameAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-income-tax-paid-net-of-refunds-details", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-net-operating-loss-and-tax-credit-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Axis]", "documentation": "Information by name of taxing authority." } } }, "auth_ref": [ "r506", "r1230" ] }, "us-gaap_IncomeTaxAuthorityNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxAuthorityNameDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-income-tax-paid-net-of-refunds-details", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-net-operating-loss-and-tax-credit-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Domain]", "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [ "r506", "r1230" ] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r199", "r204", "r492", "r498", "r503", "r504", "r505", "r508", "r515", "r527", "r529", "r531", "r532", "r691", "r727", "r738", "r889" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-federal-and-state-income-tax-provisions-details": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-federal-and-state-income-tax-provisions-details", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeTaxExpenseBenefit", "totalLabel": "Income tax provision", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r139", "r143", "r199", "r228", "r229", "r244", "r253", "r262", "r496", "r498", "r528", "r704", "r851", "r852", "r853", "r889" ] }, "us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxPaidStateAndLocalAfterRefundReceived", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-income-tax-paid-net-of-refunds-details" ], "lang": { "en-us": { "role": { "label": "Income tax paid, state and local, net of refunds", "documentation": "Amount, after income tax refund received, of cash paid to state and local tax jurisdictions for tax on income." } } }, "auth_ref": [ "r195", "r516" ] }, "nby_IncomeTaxPaymentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "IncomeTaxPaymentPolicyTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Income Tax Payment [Policy Text Block]", "documentation": "The policy disclosure for income tax payment." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r178", "r494", "r495", "r508", "r509", "r514", "r519", "r732" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Change in valuation allowance, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r502", "r889", "r1224" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "US Federal Statutory Tax Rate, Amount", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r498", "r889" ] }, "nby_IncomeTaxReconciliationLimitationOfNetOperatingLossAndCreditsDueToOwnershipChange": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "IncomeTaxReconciliationLimitationOfNetOperatingLossAndCreditsDueToOwnershipChange", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Limitation of net operating losses and credits due to ownership change, Amount", "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) for limitations of net operating loss and credits due to ownership change." } } }, "auth_ref": [] }, "nby_IncomeTaxReconciliationLimitationOfNetOperatingLossAndCreditsDueToOwnershipChangePercent": { "xbrltype": "percentItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "IncomeTaxReconciliationLimitationOfNetOperatingLossAndCreditsDueToOwnershipChangePercent", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Limitation of net operating losses and credits due to ownership change, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) for net of operating loss and credits due to ownership change." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationOtherAdjustments", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Other, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r889", "r1224", "r1225" ] }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "State and Local income taxes, net of federal income tax effect, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } }, "auth_ref": [ "r501", "r889", "r1224" ] }, "us-gaap_IncomeTaxUncertaintiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxUncertaintiesPolicy", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Income Tax Uncertainties, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for tax positions taken in the tax return filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other types of contingencies related to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable and accrued liabilities", "label": "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "terseLabel": "Accounts payable and accrued liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "terseLabel": "Accounts receivable", "negatedTerseLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInInventories", "negatedTerseLabel": "Inventory", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liabilities", "label": "us-gaap_IncreaseDecreaseInOperatingLeaseLiability", "terseLabel": "Operating lease liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r1007", "r1071" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInOtherOperatingAssets", "negatedLabel": "Other assets", "negatedTerseLabel": "Other assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedTerseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r7" ] }, "nby_InitialSeriesDPreferredPurchaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "InitialSeriesDPreferredPurchaseMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Initial Series D Preferred Purchase [Member]", "documentation": "Represents the Initial Series D Preferred Purchase." } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingArrLineItems", "auth_ref": [ "r980" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r964", "r983" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r964", "r983" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flowsA866F64D-8A89-45C0-926D-49809D27BFD0" ], "lang": { "en-us": { "role": { "label": "Interest paid in continuing operations", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r191", "r193", "r194" ] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InterestPayableCurrent", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-5-accrued-liabilities-summary-of-accrued-liabilities-details", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Interest on Unsecured Convertible Notes", "terseLabel": "Interest Payable, Current", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r73" ] }, "us-gaap_InternalRevenueServiceIRSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InternalRevenueServiceIRSMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-net-operating-loss-and-tax-credit-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Internal Revenue Service (IRS) [Member]", "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity." } } }, "auth_ref": [] }, "nby_IssuanceMarch252024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "IssuanceMarch252024Member", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Issuance, March 25, 2024 [Member]", "documentation": "Represents the issuance at March 25, 2024." } } }, "auth_ref": [] }, "nby_January2026PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "January2026PrivatePlacementMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "January 2026 Private Placement [Member]", "documentation": "Represents the January 2026 Private Placement." } } }, "auth_ref": [] }, "nby_June2024WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "June2024WarrantMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details" ], "lang": { "en-us": { "role": { "label": "June 2024 Warrant [Member]", "documentation": "Represents the June 2024 warrants." } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LeaseContractualTermAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies", "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": [ "r656", "r1006" ] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LeaseContractualTermDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies", "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": [ "r656", "r1006" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-tables" ], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1270" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LegalEntityAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets", "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows4D8E0948-3376-4886-A031-7AF56055462E", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flowsA866F64D-8A89-45C0-926D-49809D27BFD0", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations", "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information", "http://www.novabaypharma.com/20251231/role/statement-note-1-organization", "http://www.novabaypharma.com/20251231/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-options-outstanding-details", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-tables", "http://www.novabaypharma.com/20251231/role/statement-note-12-employee-benefit-plan", "http://www.novabaypharma.com/20251231/role/statement-note-12-employee-benefit-plan-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-tables", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-tables", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-tables", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations-disposal-groups-including-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations-tables", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-federal-and-state-income-tax-provisions-details", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-loss-before-provision-for-income-taxes-details", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-income-tax-paid-net-of-refunds-details", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-net-operating-loss-and-tax-credit-carryforwards-details", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-tables", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-unrecognized-tax-benefit-details", "http://www.novabaypharma.com/20251231/role/statement-note-18-related-party-transactions", "http://www.novabaypharma.com/20251231/role/statement-note-18-related-party-transactions-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-cash-cash-equivalents-restricted-cash-and-restricted-cash-equivalents-details", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-earnings-per-share-basic-and-diluted-details", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-tables", "http://www.novabaypharma.com/20251231/role/statement-note-4-prepaid-expenses-and-other-current-assets", "http://www.novabaypharma.com/20251231/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details", "http://www.novabaypharma.com/20251231/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables", "http://www.novabaypharma.com/20251231/role/statement-note-5-accrued-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-5-accrued-liabilities-summary-of-accrued-liabilities-details", "http://www.novabaypharma.com/20251231/role/statement-note-5-accrued-liabilities-tables", "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies", "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-lease-expense-details", "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-schedule-of-future-lease-payments-details", "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-tables", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-tables", "http://www.novabaypharma.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r650" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-tables" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1271" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-schedule-of-future-lease-payments-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-schedule-of-future-lease-payments-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Total future minimum lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r655", "r1075", "r1082", "r1284" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-schedule-of-future-lease-payments-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-schedule-of-future-lease-payments-details" ], "lang": { "en-us": { "role": { "label": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r655", "r1075", "r1082", "r1284" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-schedule-of-future-lease-payments-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-schedule-of-future-lease-payments-details" ], "lang": { "en-us": { "role": { "label": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r655", "r1075", "r1082", "r1284" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-schedule-of-future-lease-payments-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Less imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r655" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r16", "r72", "r73", "r74", "r77", "r78", "r79", "r82", "r199", "r201", "r202", "r270", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r551", "r552", "r553", "r634", "r764", "r857", "r873", "r958", "r1126", "r1275", "r1276" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r91", "r133", "r700", "r940", "r945", "r946", "r1074", "r1079", "r1101", "r1263" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r74", "r166", "r199", "r201", "r202", "r270", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r551", "r552", "r553", "r634", "r940", "r1126", "r1275", "r1276" ] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r609", "r1244" ] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations-disposal-groups-including-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Total current liabilities, discontinued operations", "label": "Current liabilities, discontinued operations", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r2", "r52", "r66", "r108", "r110", "r163", "r164" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_LocalPhoneNumber", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LongTermDebtFairValue", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtFairValue", "terseLabel": "Long-Term Debt, Fair Value", "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission." } } }, "auth_ref": [ "r841", "r929", "r1244", "r1246", "r1247", "r1248", "r1259", "r1260", "r1261", "r1262" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r16", "r1119", "r1120", "r1121" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r16", "r32", "r1119", "r1120", "r1121" ] }, "nby_LossIncomeFromDiscontinuedOperationsNetOfTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "LossIncomeFromDiscontinuedOperationsNetOfTaxAttributableToParent", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "verboseLabel": "Net income from discontinued operations, net of taxes", "label": "nby_LossIncomeFromDiscontinuedOperationsNetOfTaxAttributableToParent", "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [] }, "nby_March2024WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "March2024WarrantMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "March 2024 Warrant [Member]", "documentation": "Represents the March 2024 warrant." } } }, "auth_ref": [] }, "nby_MaximumAmountPurchasableByUnderwriterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "MaximumAmountPurchasableByUnderwriterMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Maximum Amount Purchasable By Underwriter [Member]", "documentation": "Represents the maximum amount purchasable by underwriter." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MaximumMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r251", "r302", "r303", "r304", "r305", "r431", "r466", "r467", "r468", "r491", "r612", "r681", "r712", "r713", "r726", "r756", "r757", "r815", "r816", "r817", "r818", "r824", "r831", "r832", "r833", "r834", "r837", "r838", "r866", "r874", "r884", "r890", "r891", "r892", "r925", "r926", "r927", "r928", "r942", "r1128", "r1277", "r1278", "r1279", "r1280", "r1281", "r1282" ] }, "nby_MaximumPercentageOfCommonStockOutstanding": { "xbrltype": "percentItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "MaximumPercentageOfCommonStockOutstanding", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_MaximumPercentageOfCommonStockOutstanding", "terseLabel": "Maximum Percentage of Common Stock Outstanding", "documentation": "Represents maximum percentage of common stock outstanding." } } }, "auth_ref": [] }, "nby_May2023WarrantsAmendedBy2023WarrantRepriceTransactionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "May2023WarrantsAmendedBy2023WarrantRepriceTransactionMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "May 2023 Warrants Amended By 2023 Warrant Reprice Transaction [Member]", "documentation": "Represents May 2023 warrants amended by the 2023 Warrant Reprice Transaction." } } }, "auth_ref": [] }, "nby_May2023WarrantsAmendedBy2024WarrantRepriceTransactionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "May2023WarrantsAmendedBy2024WarrantRepriceTransactionMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "May 2023 Warrants Amended By 2024 Warrant Reprice Transaction [Member]", "documentation": "Represents the portion of May 2024 warrants amended by the 2024 Warrant Reprice Transaction." } } }, "auth_ref": [] }, "us-gaap_MeasurementInputExercisePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputExercisePriceMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Exercise Price [Member]", "documentation": "Measurement input using agreed upon price for exchange of underlying asset." } } }, "auth_ref": [ "r1216", "r1246", "r1247", "r1248" ] }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Dividend Rate [Member]", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year." } } }, "auth_ref": [ "r467", "r1246", "r1247", "r1248" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r465", "r1246", "r1247", "r1248" ] }, "us-gaap_MeasurementInputOptionVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputOptionVolatilityMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Option Volatility [Member]", "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns." } } }, "auth_ref": [ "r1246", "r1247", "r1248" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r466", "r925", "r1246", "r1247", "r1248" ] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r468", "r1246", "r1247", "r1248" ] }, "us-gaap_MeasurementInputSharePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputSharePriceMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Share Price [Member]", "documentation": "Measurement input using share price of saleable stock." } } }, "auth_ref": [ "r1246", "r1247", "r1248" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r464", "r465", "r466", "r467", "r468", "r469", "r610", "r611", "r612", "r890", "r891", "r892", "r925" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r610", "r611", "r612", "r890", "r891", "r892", "r925" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MinimumMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r251", "r302", "r303", "r304", "r305", "r431", "r466", "r467", "r468", "r491", "r612", "r681", "r712", "r713", "r726", "r756", "r757", "r815", "r816", "r817", "r818", "r824", "r831", "r832", "r833", "r834", "r837", "r838", "r866", "r874", "r884", "r890", "r891", "r892", "r925", "r926", "r927", "r942", "r1128", "r1277", "r1278", "r1279", "r1280", "r1281", "r1282" ] }, "nby_ModificationOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ModificationOfWarrants", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Non-cash loss on modification of warrants", "terseLabel": "Modification of Warrants", "documentation": "The amount of noncash expense from modification of warrants." } } }, "auth_ref": [] }, "nby_MonthlyConsultingFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "MonthlyConsultingFee", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-18-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_MonthlyConsultingFee", "terseLabel": "Monthly Consulting Fee", "documentation": "Amount of monthly consulting fee." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r981" ] }, "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations-disposal-groups-including-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Net increase in cash and cash equivalents, discontinued operations", "label": "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations", "terseLabel": "Net increase in cash and cash equivalents, discontinued operations", "documentation": "Amount of cash inflow (outflow) from operating, investing, and financing activities; attributable to discontinued operation." } } }, "auth_ref": [ "r103" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash provided by financing activities, continuing operations", "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit." } } }, "auth_ref": [ "r192" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash used in operating activities, continuing operations", "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity." } } }, "auth_ref": [ "r103", "r104", "r105" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 0.0 }, "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity" ], "lang": { "en-us": { "role": { "label": "Net loss", "totalLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r95", "r105", "r135", "r156", "r164", "r176", "r177", "r181", "r199", "r201", "r202", "r207", "r214", "r219", "r220", "r222", "r223", "r224", "r228", "r229", "r236", "r270", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r349", "r352", "r355", "r361", "r477", "r540", "r549", "r606", "r634", "r701", "r785", "r806", "r807", "r851", "r852", "r853", "r956", "r1126" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-earnings-per-share-basic-and-diluted-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Net loss", "label": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "totalLabel": "Net loss attributable to common stockholders", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r156", "r183", "r219", "r220", "r222", "r223", "r231", "r232", "r237", "r240", "r352", "r355", "r361", "r549" ] }, "nby_NetProceedsFromIssuanceOfStockAnWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "NetProceedsFromIssuanceOfStockAnWarrants", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_NetProceedsFromIssuanceOfStockAnWarrants", "terseLabel": "Net Proceeds From Issuance of Stock an Warrants", "documentation": "The cash inflow from the issuance of stock and warrant, net of discounts and commission." } } }, "auth_ref": [] }, "nby_NeutrophaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "NeutrophaseMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations-disposal-groups-including-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "NeutroPhase [Member]", "documentation": "Represents the distribution agreement for NeutroPhase." } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-cash-cash-equivalents-restricted-cash-and-restricted-cash-equivalents-details", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-earnings-per-share-basic-and-diluted-details", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-tables" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "documentation": "Disclosure of information about change in accounting principle or amendment to accounting standards or both. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards and other change in accounting principle." } } }, "auth_ref": [ "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r188", "r189", "r190", "r213", "r214", "r215", "r216", "r217", "r218", "r222", "r230", "r243", "r266", "r267", "r271", "r272", "r273", "r274", "r287", "r288", "r299", "r346", "r347", "r348", "r349", "r475", "r476", "r477", "r478", "r521", "r522", "r523", "r524", "r525", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r629", "r630", "r644", "r645", "r659", "r660", "r661", "r662", "r663", "r664", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r730" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_NewJerseyDivisionOfTaxationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NewJerseyDivisionOfTaxationMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-income-tax-paid-net-of-refunds-details" ], "lang": { "en-us": { "role": { "label": "New Jersey Division of Taxation [Member]", "documentation": "Designated tax department of the government of the state of New Jersey." } } }, "auth_ref": [] }, "us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NewYorkStateDivisionOfTaxationAndFinanceMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-income-tax-paid-net-of-refunds-details" ], "lang": { "en-us": { "role": { "label": "New York State Division of Taxation and Finance [Member]", "documentation": "Designated tax department of the government of the state of New York." } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrAdoptedFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r981" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrTrmntdFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r981" ] }, "nby_NoncashExpenseIncurredToObtainConsentOfSecuredNoteHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "NoncashExpenseIncurredToObtainConsentOfSecuredNoteHolders", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Non-cash expense incurred to obtain consent of Secured Convertible Note holders", "documentation": "Amount of noncash expense incurred to obtain consent of secured note holders." } } }, "auth_ref": [] }, "nby_NoncashGainOnChangesInCombinedDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "NoncashGainOnChangesInCombinedDerivativeLiability", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Non-cash loss on changes in fair value of embedded derivative liability", "documentation": "The amount of gain on changes in combined derivative liability." } } }, "auth_ref": [] }, "us-gaap_NonmonetaryTransactionTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NonmonetaryTransactionTypeAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-1-organization", "http://www.novabaypharma.com/20251231/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Nonmonetary Transaction Type [Axis]", "documentation": "Information by nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange." } } }, "auth_ref": [ "r657", "r658", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939" ] }, "us-gaap_NonmonetaryTransactionTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NonmonetaryTransactionTypeDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-1-organization", "http://www.novabaypharma.com/20251231/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Nonmonetary Transaction Type [Domain]", "documentation": "Identifies the nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange." } } }, "auth_ref": [ "r657", "r658", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939" ] }, "nby_NotSubjectToExpirationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "NotSubjectToExpirationMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-net-operating-loss-and-tax-credit-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Not Subject to Expiration [Member]", "documentation": "Represents indefinite life." } } }, "auth_ref": [] }, "nby_NoteToFinancialStatementDetailsTextual": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "NoteToFinancialStatementDetailsTextual", "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "auth_ref": [] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NotesPayableCurrent", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Bridge Loan", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r72", "r73" ] }, "nby_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "auth_ref": [] }, "nby_November2021WarrantsAdjustedFrom2023PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "November2021WarrantsAdjustedFrom2023PrivatePlacementMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "November 2021 Warrants Adjusted From 2023 Private Placement [Member]", "documentation": "Related to warrants." } } }, "auth_ref": [] }, "nby_November2022WarrantsAmendedBy2024WarrantRepriceTransactionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "November2022WarrantsAmendedBy2024WarrantRepriceTransactionMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "November 2022 Warrants Amended By 2024 Warrant Reprice Transaction [Member]", "documentation": "Represents the November 2022 warrants that were amended by the 2024 Warrant Reprice Transaction." } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfOperatingSegments", "terseLabel": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r863", "r1093" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-1-organization-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfReportableSegments", "terseLabel": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r859", "r865", "r1093" ] }, "nby_October2025PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "October2025PreFundedWarrantsMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details" ], "lang": { "en-us": { "role": { "label": "October 2025 Pre-Funded Warrants [Member]", "documentation": "Represents the October 2025 pre-funded warrants." } } }, "auth_ref": [] }, "nby_OfficeSpaceForCorporateHeadquartersInEmeryvilleCaliforniaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "OfficeSpaceForCorporateHeadquartersInEmeryvilleCaliforniaMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies", "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Office Space for Corporate Headquarters in Emeryville, California [Member]", "documentation": "Represents office space for its corporate headquarters located in Emeryville, California." } } }, "auth_ref": [] }, "us-gaap_OpenTaxYear": { "xbrltype": "gYearListItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OpenTaxYear", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_OpenTaxYear", "terseLabel": "Open Tax Year", "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format." } } }, "auth_ref": [ "r506" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingExpenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [ "r853" ] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Operating loss", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r137", "r851", "r853", "r858", "r1092", "r1094", "r1095", "r1096", "r1097" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-lease-expense-details" ], "lang": { "en-us": { "role": { "label": "Operating lease \u2013 expense", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r651", "r931" ] }, "us-gaap_OperatingLeaseImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseImpairmentLoss", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeaseImpairmentLoss", "terseLabel": "Operating Lease, Impairment Loss", "documentation": "Amount of loss from impairment of right-of-use asset from operating lease." } } }, "auth_ref": [ "r1269" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-schedule-of-future-lease-payments-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-schedule-of-future-lease-payments-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeaseLiability", "terseLabel": "Total", "totalLabel": "Total", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r648" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-schedule-of-future-lease-payments-details": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 0.0 }, "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets", "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-schedule-of-future-lease-payments-details" ], "lang": { "en-us": { "role": { "label": "Operating lease liabilities", "terseLabel": "Operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r648" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 }, "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-schedule-of-future-lease-payments-details": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets", "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-schedule-of-future-lease-payments-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liabilities-non-current", "label": "us-gaap_OperatingLeaseLiabilityNoncurrent", "terseLabel": "Operating lease liability- non-current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r648" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-lease-expense-details" ], "lang": { "en-us": { "role": { "label": "Operating lease \u2013 included in operating cash flow", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r649", "r652" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Operating lease right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r647" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Non-cash right-of-use amortization", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r1072" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-lease-expense-details" ], "lang": { "en-us": { "role": { "label": "Weighted-average discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r654", "r931" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-lease-expense-details" ], "lang": { "en-us": { "role": { "label": "Weighted-average remaining lease term (in years) (Year)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r653", "r931" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-net-operating-loss-and-tax-credit-carryforwards-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Net operating losses", "label": "us-gaap_OperatingLossCarryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r518" ] }, "nby_OptionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "OptionPeriod", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_OptionPeriod", "terseLabel": "Option Period", "documentation": "Period of the option." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-1-organization" ], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r124", "r157", "r159", "r161", "r728", "r729" ] }, "nby_OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "OriginalIssueDiscountSeniorSecuredConvertibleDebenturesMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Original Issue Discount Senior Secured Convertible Debentures [Member]", "documentation": "Represents Original Issue Discount Senior Secured Convertible Debentures." } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-5-accrued-liabilities-summary-of-accrued-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_OtherAccruedLiabilitiesCurrent", "terseLabel": "Other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r73" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherAssetsCurrent", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_OtherAssetsCurrent", "terseLabel": "Other", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r173", "r940" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r168" ] }, "us-gaap_OtherCommitmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherCommitmentsTable", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies", "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-lease-expense-details", "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-schedule-of-future-lease-payments-details", "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-tables" ], "lang": { "en-us": { "role": { "label": "Other Commitments [Table]", "documentation": "Disclosure of information about obligations resulting from other commitments." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities" ], "lang": { "en-us": { "role": { "label": "Other Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for other liabilities." } } }, "auth_ref": [ "r73", "r78", "r1117" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_OtherNonoperatingIncomeExpense", "terseLabel": "Other expense, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r98", "r920" ] }, "nby_OtherRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "OtherRevenueMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details" ], "lang": { "en-us": { "role": { "label": "Other Revenue [Member]", "documentation": "Represents other revenue." } } }, "auth_ref": [] }, "nby_OtherTaxAgencyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "OtherTaxAgencyMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-income-tax-paid-net-of-refunds-details" ], "lang": { "en-us": { "role": { "label": "Other Tax Agency [Member]", "documentation": "Represents other tax agencies." } } }, "auth_ref": [] }, "nby_OtherWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "OtherWarrantsMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details" ], "lang": { "en-us": { "role": { "label": "Other Warrants [Member]", "documentation": "Represents other warrants." } } }, "auth_ref": [] }, "us-gaap_OverAllotmentOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OverAllotmentOptionMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Over-Allotment Option [Member]", "documentation": "Right given to the underwriter to sell additional shares over the initial allotment." } } }, "auth_ref": [] }, "nby_PaymentForConsultingFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "PaymentForConsultingFees", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-18-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_PaymentForConsultingFees", "terseLabel": "Payment for Consulting Fees", "documentation": "Amount of cash outflow due to consulting fees during the period." } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsForRepurchaseOfConvertiblePreferredStock", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock", "negatedLabel": "Payment on redemption of Series F Preferred Stock", "documentation": "The cash outflow to reacquire preferred stock originally issued and identified as a security that can be exchanged for another type of financial security. This repurchased stock is held in treasury." } } }, "auth_ref": [ "r101" ] }, "us-gaap_PaymentsForRepurchaseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsForRepurchaseOfWarrants", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsForRepurchaseOfWarrants", "negatedLabel": "Payments on warrants purchase", "terseLabel": "Payments for Repurchase of Warrants", "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt." } } }, "auth_ref": [ "r101" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsOfDebtIssuanceCosts", "negatedLabel": "Cash debt issuance cost", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r23" ] }, "us-gaap_PaymentsOfDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsOfDividends", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsOfDividends", "negatedLabel": "Dividend paid", "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests." } } }, "auth_ref": [ "r101" ] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsOfDividendsCommonStock", "terseLabel": "Payments of Ordinary Dividends, Common Stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": [ "r101" ] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsOfStockIssuanceCosts", "terseLabel": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r22" ] }, "nby_PaymentsToWarrantsExchange": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "PaymentsToWarrantsExchange", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "nby_PaymentsToWarrantsExchange", "negatedLabel": "Cash payment pursuant to warrant exchange", "documentation": "The amount of payments due to warrants exchange." } } }, "auth_ref": [] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-12-employee-benefit-plan" ], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Text Block]", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": [ "r389", "r390", "r391", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r425", "r426", "r427", "r881" ] }, "nby_PercentOfClosingPrice": { "xbrltype": "percentItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "PercentOfClosingPrice", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_PercentOfClosingPrice", "terseLabel": "Percent of Closing Price", "documentation": "The percentage of the closing price." } } }, "auth_ref": [] }, "nby_PhaseOneHealthLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "PhaseOneHealthLLCMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations-disposal-groups-including-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "Phase One Health, LLC [Member]", "documentation": "Represents Phase One Health, LLC." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PlanNameAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1217", "r1218", "r1219", "r1220", "r1221" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PlanNameDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1217", "r1218", "r1219", "r1220", "r1221" ] }, "nby_PolicyTable": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "PolicyTable", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "nby_PolicyTable" } } }, "auth_ref": [] }, "us-gaap_PolicyTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PolicyTextBlockAbstract", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "auth_ref": [] }, "nby_PostAmendmentJune142024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "PostAmendmentJune142024Member", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Post amendment June 14, 2024 [Member]", "documentation": "Represents period after the amendment on June 14, 2024." } } }, "auth_ref": [] }, "nby_PreamendmentJune142024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "PreamendmentJune142024Member", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Pre-amendment June 14, 2024 [Member]", "documentation": "Represents period prior to the amendment on June 14, 2024." } } }, "auth_ref": [] }, "us-gaap_PreferredStockConvertibleConversionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockConvertibleConversionPrice", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PreferredStockConvertibleConversionPrice", "terseLabel": "Preferred Stock, Convertible, Conversion Price (in dollars per share)", "documentation": "Per share conversion price of preferred stock." } } }, "auth_ref": [ "r365" ] }, "us-gaap_PreferredStockConvertibleConversionRatio": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockConvertibleConversionRatio", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PreferredStockConvertibleConversionRatio", "terseLabel": "Preferred Stock, Convertible, Conversion Ratio", "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted." } } }, "auth_ref": [ "r365" ] }, "us-gaap_PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-earnings-per-share-basic-and-diluted-details" ], "lang": { "en-us": { "role": { "label": "Less: Increase to accumulated deficit due to adjustment to Preferred Stock conversion price", "negatedLabel": "Less: Increase to accumulated deficit due to adjustment to Preferred Stock conversion price", "documentation": "Amount of decrease in net income available to common shareholder for down round feature triggered for convertible preferred stock." } } }, "auth_ref": [ "r233", "r240" ] }, "us-gaap_PreferredStockConvertibleSharesIssuable": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockConvertibleSharesIssuable", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PreferredStockConvertibleSharesIssuable", "terseLabel": "Preferred Stock, Convertible, Shares Issuable", "documentation": "Number of common shares issuable upon conversion of preferred stock." } } }, "auth_ref": [ "r365" ] }, "nby_PreferredStockMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "PreferredStockMeasurementInput", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "nby_PreferredStockMeasurementInput", "terseLabel": "Measurement Input", "documentation": "Measurement input for preferred stock." } } }, "auth_ref": [] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity" ], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r948", "r949", "r952", "r953", "r954", "r955", "r1316", "r1319" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred stock par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r84", "r363" ] }, "nby_PreferredStockPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "PreferredStockPolicyTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Preferred Stock [Policy Text Block]", "documentation": "Represents the significant accounting policy referring to preferred stock." } } }, "auth_ref": [] }, "nby_PreferredStockPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "PreferredStockPurchaseAgreementMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "2025 Preferred Stock Purchase Agreement [Member]", "documentation": "Represents the 2025 Preferred Stock Purchase Agreement." } } }, "auth_ref": [] }, "us-gaap_PreferredStockRedemptionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockRedemptionAmount", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PreferredStockRedemptionAmount", "terseLabel": "Preferred Stock, Redemption Amount", "documentation": "The redemption (or callable) amount of currently redeemable preferred stock. Includes amounts representing dividends not currently declared or paid but which will be payable under the redemption features or for which ultimate payment is solely within the control of the issuer." } } }, "auth_ref": [ "r38", "r83", "r594" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized (in shares)", "terseLabel": "Preferred Stock, Shares Authorized (in shares)", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r84", "r766" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued (in shares)", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r84", "r363" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding (in shares)", "terseLabel": "Preferred Stock, Shares Outstanding (in shares)", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r84", "r766", "r784", "r1319", "r1320" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, value, issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r84", "r351", "r358", "r696", "r940" ] }, "nby_PrefundedWarrants2024PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "PrefundedWarrants2024PublicOfferingMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "Prefunded Warrants 2024 Public Offering [Member]", "documentation": "Represents the prefunded warrants that are part of the 2024 Public Offering." } } }, "auth_ref": [] }, "nby_PrefundedWarrantsExercisedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "PrefundedWarrantsExercisedDuringPeriod", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details" ], "lang": { "en-us": { "role": { "label": "Pre-funded Warrants exercised (in shares)", "documentation": "The number of pre-funded warrants exercised during the period." } } }, "auth_ref": [] }, "nby_PrefundedWarrantsIssuedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "PrefundedWarrantsIssuedDuringPeriod", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details" ], "lang": { "en-us": { "role": { "label": "Pre-funded Warrants granted (in shares)", "documentation": "The number of pre-funded warrants issued during the period." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets", "http://www.novabaypharma.com/20251231/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "terseLabel": "Total prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1017" ] }, "nby_PrepaidExpensesAndOtherCurrentAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-4-prepaid-expenses-and-other-current-assets" ], "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Other Current Assets [Text Block]", "documentation": "The entire disclosure for prepaid expenses and other assets expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PrepaidInsurance", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details" ], "lang": { "en-us": { "role": { "label": "Prepaid insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r845", "r867", "r1104" ] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r1014" ] }, "nby_PriorToAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "PriorToAdjustmentMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Prior to Adjustment [Member]", "documentation": "Related to prior to adjustment." } } }, "auth_ref": [] }, "nby_PriorToRatchetMarch242024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "PriorToRatchetMarch242024Member", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Prior to Ratchet, March 24, 2024 [Member]", "documentation": "Represents Prior to Ratchet, March 24, 2024." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromDisposalCryptoAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromDisposalCryptoAsset", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromDisposalCryptoAsset", "terseLabel": "Proceeds from Disposal, Crypto Asset", "documentation": "Amount of cash inflow from disposal of crypto asset. Excludes crypto asset held for platform user." } } }, "auth_ref": [ "r1068" ] }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromDivestitureOfBusinesses", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from divestiture", "label": "us-gaap_ProceedsFromDivestitureOfBusinesses", "terseLabel": "Proceeds from Divestiture of Businesses", "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period." } } }, "auth_ref": [ "r20" ] }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Net proceeds from issuance of Preferred Stock", "terseLabel": "Proceeds from Issuance of Preferred Stock and Preference Stock", "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation." } } }, "auth_ref": [ "r4" ] }, "nby_ProceedsFromIssuanceOfPreferredStockAndPreferenceStockNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStockNet", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_ProceedsFromIssuanceOfPreferredStockAndPreferenceStockNet", "terseLabel": "Proceeds from Issuance of Preferred Stock and Preference Stock, Net", "documentation": "Net proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-1-organization-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromIssuanceOfPrivatePlacement", "terseLabel": "Proceeds from Issuance of Private Placement", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": [ "r4" ] }, "nby_ProceedsFromIssuanceOfStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ProceedsFromIssuanceOfStockAndWarrants", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_ProceedsFromIssuanceOfStockAndWarrants", "terseLabel": "Proceeds from Issuance of Stock and Warrants", "documentation": "The cash inflow from the issuance of stock and warrant." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of October 2025 pre-funded warrants", "terseLabel": "Proceeds from Issuance of Warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.novabaypharma.com/20251231/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of common stock and pre-funded warrants the 2024 Public Offering, net of issuance costs", "terseLabel": "Proceeds from Issuance or Sale of Equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r4", "r733" ] }, "us-gaap_ProceedsFromNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromNotesPayable", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Bridge Loan", "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r21" ] }, "us-gaap_ProceedsFromSaleOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromSaleOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromSaleOfIntangibleAssets", "terseLabel": "Proceeds from Sale of Intangible Assets", "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r99" ] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "Proceeds from Warrants Exercise", "terseLabel": "Proceeds from Warrant Exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r1069" ] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProductMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details" ], "lang": { "en-us": { "role": { "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r850", "r853", "r875", "r876" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r264", "r682", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r842", "r850", "r852", "r853", "r875", "r876", "r941", "r942", "r943", "r944", "r947", "r1005", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1124", "r1125", "r1287", "r1288", "r1289", "r1290", "r1291", "r1292", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r264", "r682", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r842", "r850", "r852", "r853", "r875", "r876", "r941", "r942", "r943", "r944", "r947", "r1005", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1124", "r1125", "r1287", "r1288", "r1289", "r1290", "r1291", "r1292", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RangeAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r251", "r302", "r303", "r304", "r305", "r390", "r431", "r466", "r467", "r468", "r474", "r491", "r612", "r678", "r679", "r681", "r712", "r713", "r726", "r756", "r757", "r815", "r816", "r817", "r818", "r824", "r831", "r832", "r833", "r834", "r837", "r838", "r866", "r874", "r884", "r890", "r891", "r892", "r925", "r926", "r927", "r928", "r942", "r950", "r1122", "r1128", "r1247", "r1278", "r1279", "r1280", "r1281", "r1282" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RangeMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r251", "r302", "r303", "r304", "r305", "r390", "r431", "r466", "r467", "r468", "r474", "r491", "r612", "r678", "r679", "r681", "r712", "r713", "r726", "r756", "r757", "r815", "r816", "r817", "r818", "r824", "r831", "r832", "r833", "r834", "r837", "r838", "r866", "r874", "r884", "r890", "r891", "r892", "r925", "r926", "r927", "r928", "r942", "r950", "r1122", "r1128", "r1247", "r1278", "r1279", "r1280", "r1281", "r1282" ] }, "nby_ReclassificationOfEmbeddedDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ReclassificationOfEmbeddedDerivativeLiability", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity" ], "lang": { "en-us": { "role": { "label": "Reclassification of embedded derivative liability", "documentation": "Represents the reclassification of an embedded derivative liability." } } }, "auth_ref": [] }, "nby_ReclassifyPrivatePlacementWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ReclassifyPrivatePlacementWarrants", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity" ], "lang": { "en-us": { "role": { "label": "Reclassification of Warrants from liability", "documentation": "Represents the amount of reclassification of private placement warrants." } } }, "auth_ref": [] }, "us-gaap_RedeemablePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RedeemablePreferredStockMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity" ], "lang": { "en-us": { "role": { "label": "Redeemable Preferred Stock [Member]", "documentation": "Description of type or class of redeemable preferred stock. For instance, cumulative preferred stock, noncumulative preferred stock, convertible or series." } } }, "auth_ref": [ "r17", "r199", "r202", "r270", "r308", "r310", "r311", "r312", "r315", "r316", "r350", "r351", "r353", "r354", "r356", "r360", "r1078" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-18-related-party-transactions" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r665", "r666", "r667", "r669", "r671", "r739", "r740", "r741", "r791", "r792", "r793", "r812", "r814" ] }, "us-gaap_RepaymentsOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RepaymentsOfConvertibleDebt", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfConvertibleDebt", "negatedLabel": "Payments on Secured Convertible Notes", "terseLabel": "Repayments of Convertible Debt", "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r102" ] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfNotesPayable", "negatedLabel": "Payment on Bridge Note", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r102" ] }, "nby_ReportingDateMarch312024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ReportingDateMarch312024Member", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Reporting Date, March 31, 2024 [Member]", "documentation": "Represents reporting date of March 31, 2024." } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r199", "r208", "r209", "r321", "r366", "r670", "r680", "r692", "r847", "r848", "r849", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1237", "r1238", "r1239", "r1240" ] }, "srt_RestatementAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RestatementAdjustmentMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-details-textual" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period, Adjustment [Member]" } } }, "auth_ref": [ "r210", "r211", "r212", "r226", "r227", "r243", "r604", "r605", "r645", "r1000", "r1001", "r1003", "r1004", "r1010", "r1011", "r1087", "r1098" ] }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RestatementAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-details-textual" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]" } } }, "auth_ref": [ "r149", "r155", "r156", "r158", "r187", "r210", "r211", "r212", "r214", "r215", "r219", "r220", "r221", "r222", "r225", "r226", "r227", "r228", "r229", "r230", "r243", "r272", "r273", "r348", "r349", "r477", "r537", "r538", "r540", "r541", "r548", "r549", "r600", "r604", "r605", "r606", "r645", "r663", "r664", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r730", "r1098" ] }, "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RestatementDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-details-textual" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]" } } }, "auth_ref": [ "r149", "r155", "r156", "r158", "r187", "r210", "r211", "r212", "r214", "r215", "r219", "r220", "r221", "r222", "r225", "r226", "r227", "r228", "r229", "r230", "r243", "r272", "r273", "r348", "r349", "r477", "r537", "r538", "r540", "r541", "r548", "r549", "r600", "r604", "r605", "r606", "r645", "r663", "r664", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r730", "r1098" ] }, "us-gaap_RestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestrictedCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-cash-cash-equivalents-restricted-cash-and-restricted-cash-equivalents-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Restricted cash included in other assets", "label": "us-gaap_RestrictedCashAndCashEquivalents", "documentation": "Amount of cash and cash equivalent restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r24", "r126", "r167", "r196", "r695" ] }, "nby_RestrictedCashHeldAsACertificateOfDepositFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "RestrictedCashHeldAsACertificateOfDepositFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Restricted cash held as a certificate of deposit", "label": "nby_RestrictedCashHeldAsACertificateOfDepositFairValueDisclosure", "documentation": "Fair value portion of restricted cash held as a certificate of deposit." } } }, "auth_ref": [] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestrictedStockMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r1091", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1217", "r1218", "r1219", "r1220", "r1221" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r88", "r120", "r699", "r720", "r725", "r737", "r767", "r940" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RetainedEarningsMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r148", "r155", "r156", "r210", "r211", "r212", "r215", "r224", "r227", "r229", "r271", "r274", "r288", "r348", "r477", "r521", "r522", "r536", "r537", "r538", "r541", "r548", "r549", "r582", "r585", "r586", "r589", "r604", "r644", "r646", "r716", "r718", "r742", "r1319" ] }, "us-gaap_RetirementPlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RetirementPlanNameAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-12-employee-benefit-plan", "http://www.novabaypharma.com/20251231/role/statement-note-12-employee-benefit-plan-details-textual" ], "lang": { "en-us": { "role": { "label": "Retirement Plan Name [Axis]", "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans." } } }, "auth_ref": [ "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r884", "r1002", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193" ] }, "us-gaap_RetirementPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RetirementPlanNameDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-12-employee-benefit-plan", "http://www.novabaypharma.com/20251231/role/statement-note-12-employee-benefit-plan-details-textual" ], "lang": { "en-us": { "role": { "label": "Retirement Plan Name [Domain]", "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans." } } }, "auth_ref": [ "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r884", "r1002", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r144", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r840" ] }, "nby_ReverseStockSplitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ReverseStockSplitMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-1-organization", "http://www.novabaypharma.com/20251231/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Reverse Stock Split [Member]", "documentation": "The conversion of a reverse stock split where there is a reduction in the shares outstanding." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrAdoptedFlag", "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r981" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrTrmntdFlag", "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r981" ] }, "nby_SKYTokensMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "SKYTokensMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-1-organization", "http://www.novabaypharma.com/20251231/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "SKY Tokens [Member]", "documentation": "Represents SKY tokens." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "http://www.novabaypharma.com/20251231/role/statement-note-1-organization", "http://www.novabaypharma.com/20251231/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ScenarioForecastMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-1-organization", "http://www.novabaypharma.com/20251231/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]" } } }, "auth_ref": [ "r436" ] }, "srt_ScenarioPreviouslyReportedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ScenarioPreviouslyReportedMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-details-textual" ], "lang": { "en-us": { "role": { "label": "Previously Reported [Member]" } } }, "auth_ref": [ "r149", "r155", "r156", "r210", "r212", "r214", "r215", "r219", "r220", "r229", "r243", "r348", "r349", "r477", "r537", "r540", "r541", "r548", "r549", "r600", "r604", "r605", "r645", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r730", "r1008", "r1009", "r1010", "r1086", "r1087", "r1098", "r1102", "r1103", "r1243", "r1272", "r1273" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-1-organization", "http://www.novabaypharma.com/20251231/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": [ "r160", "r162", "r230", "r436", "r998" ] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Accounts and Financing Receivables [Table]", "documentation": "Disclosure of information about accounts and financing receivables. Includes, but is not limited to, amount of receivable and allowance for credit loss." } } }, "auth_ref": [ "r86", "r92", "r269", "r1100" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-5-accrued-liabilities-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r29" ] }, "nby_ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of the components of cash, cash equivalents, restricted cash and restricted cash equivalents." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r1232" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r1229" ] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-12-employee-benefit-plan", "http://www.novabaypharma.com/20251231/role/statement-note-12-employee-benefit-plan-details-textual" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan [Table]", "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r11", "r43", "r44", "r45", "r46", "r404", "r405", "r406", "r408", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424" ] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-tables", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-tables", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-tables", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations-tables" ], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r10", "r15", "r18", "r52", "r58", "r59", "r60", "r61", "r62", "r67", "r69", "r70", "r111", "r1115", "r1116" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r1090" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r500", "r889", "r1224" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-4-prepaid-expenses-and-other-current-assets", "http://www.novabaypharma.com/20251231/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details", "http://www.novabaypharma.com/20251231/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables" ], "lang": { "en-us": { "role": { "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": [ "r275", "r276", "r277", "r278", "r279", "r683", "r839", "r843", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919" ] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": [ "r1074", "r1080" ] }, "nby_ScheduleOfIncomeTaxPaidNetOfRefundsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ScheduleOfIncomeTaxPaidNetOfRefundsTableTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Income Tax Paid, Net of Refunds [Table Text Block]", "documentation": "A tabular disclosure of the income tax paid, net of refunds by jurisdiction." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfProductInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfProductInformationTable", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-1-organization", "http://www.novabaypharma.com/20251231/role/statement-note-1-organization-details-textual" ], "lang": { "en-us": { "role": { "label": "Nature of Operation, Product Information, Concentration of Risk [Table]", "documentation": "Disclosure of information about concentration risk of product within nature of operation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-18-related-party-transactions", "http://www.novabaypharma.com/20251231/role/statement-note-18-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": [ "r199", "r206", "r207", "r668", "r669", "r670", "r789", "r790", "r793" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-options-outstanding-details", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r438", "r439", "r441", "r442", "r443", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r464", "r465", "r466", "r467", "r468", "r469", "r474" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-tables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r13", "r14", "r122" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r36", "r37", "r39", "r40", "r41", "r42", "r117", "r119", "r120", "r170", "r171", "r172", "r246", "r363", "r364", "r366", "r368", "r371", "r376", "r378", "r578", "r733", "r734", "r735", "r736", "r874", "r997", "r1074", "r1076" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r1132" ] }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in unrecognized tax benefits." } } }, "auth_ref": [ "r507", "r888" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r959" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r961" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r263", "r265", "r860", "r861", "r864" ] }, "nby_September2022November2022AndMay2023WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "September2022November2022AndMay2023WarrantsMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "September 2022, November 2022, and May 2023 Warrants [Member]", "documentation": "Represents the September 2022, November 2022, and May 2023 warrants." } } }, "auth_ref": [] }, "nby_September2022WarrantsAmendedIn2023PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "September2022WarrantsAmendedIn2023PrivatePlacementMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "September 2022 Warrants Amended in 2023 Private Placement [Member]", "documentation": "Represents the portion of September 2022 warrants that were amended in the 2023 Private Placement." } } }, "auth_ref": [] }, "nby_September2022WarrantsAmendedIn2024WarrantRepriseTransactionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "September2022WarrantsAmendedIn2024WarrantRepriseTransactionMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "September 2022 Warrants Amended in 2024 Warrant Reprise Transaction [Member]", "documentation": "Represents September 2022 warrants amended in the 2024 Warrant Reprise Transaction." } } }, "auth_ref": [] }, "nby_September2022WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "September2022WarrantsMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details" ], "lang": { "en-us": { "role": { "label": "September 2022 Warrants [Member]", "documentation": "Represents the September 2022 warrants." } } }, "auth_ref": [] }, "us-gaap_SeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SeriesBPreferredStockMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets", "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "Series B Preferred Stock [Member]", "documentation": "Series B preferred stock." } } }, "auth_ref": [ "r1015", "r1016", "r1130", "r1131" ] }, "nby_SeriesBPreferredStockPostsplitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "SeriesBPreferredStockPostsplitMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "Series B Preferred Stock, Post-split [Member]", "documentation": "Related to post split stock." } } }, "auth_ref": [] }, "us-gaap_SeriesCPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SeriesCPreferredStockMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Series C Preferred Stock [Member]", "documentation": "Series C preferred stock." } } }, "auth_ref": [ "r1015", "r1016", "r1130", "r1131" ] }, "us-gaap_SeriesDPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SeriesDPreferredStockMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Series D Preferred Stock [Member]", "documentation": "Series D preferred stock." } } }, "auth_ref": [ "r1015", "r1016", "r1130", "r1131" ] }, "us-gaap_SeriesEPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SeriesEPreferredStockMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Series E Preferred Stock [Member]", "documentation": "Series E preferred stock." } } }, "auth_ref": [ "r1015", "r1016", "r1130", "r1131" ] }, "nby_SeriesF1WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "SeriesF1WarrantsMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Series F-1 Warrants [Member]", "documentation": "Represents the Series F-1 warrants." } } }, "auth_ref": [] }, "nby_SeriesF2WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "SeriesF2WarrantsMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Series F-2 Warrants [Member]", "documentation": "Represents Series F-2 warrants." } } }, "auth_ref": [] }, "nby_SeriesF3WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "SeriesF3WarrantsMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Series F-3 Warrants [Member]", "documentation": "Related to Series F-3 Warrants." } } }, "auth_ref": [] }, "us-gaap_SeriesFPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SeriesFPreferredStockMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets", "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows4D8E0948-3376-4886-A031-7AF56055462E", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Series F Preferred Stock [Member]", "documentation": "Series F preferred stock." } } }, "auth_ref": [ "r1015", "r1016", "r1130", "r1131" ] }, "nby_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingCommonStock": { "xbrltype": "percentItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingCommonStock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingCommonStock", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase in Shares Authorized, Percentage of Outstanding Common Stock", "documentation": "Annual increase in number of shares originally approved for awards under the equity-based compensation plan expressed as a percentage of outstanding common stock." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r885" ] }, "nby_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Vested and expected to vest, weighted-average exercise price (in dollars per share)", "documentation": "As of the balance sheet date, the weighted-average exercise price for outstanding stock options and equity instruments other than options that are fully vested or expected to vest." } } }, "auth_ref": [] }, "nby_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Vested and expected to vest, weighted-average remaining contractual life (Year)", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest equity instruments other than options and options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r456" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "negatedLabel": "Restricted stock units vested (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r457" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r1222" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r887" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r47" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Options forfeited/cancelled, weighted-average exercise price (in dollars per share)", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r1201" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Restricted stock units granted (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r449" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Outstanding, aggregate intrinsic value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r47" ] }, "nby_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOfStockOwnedByShareholderMinimum": { "xbrltype": "percentItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOfStockOwnedByShareholderMinimum", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOfStockOwnedByShareholderMinimum", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percentage of Stock Owned by Shareholder, Minimum", "documentation": "Minimum percentage of a shareholder's ownership of common stock used for determining the purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "nby_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableNumber", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Vested and exercisable (in shares)", "documentation": "The number of shares into which fully or partially vested stock equity instruments other than options and options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [] }, "nby_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Exercisable, weighted-average exercise price (in dollars per share)", "documentation": "Weighted average price at which option or equity instruments other than options, holders acquired shares when converting their stock options or equity instruments other than options, into shares." } } }, "auth_ref": [] }, "nby_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableWeightedAverageRemainingContractualTerm", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Exercisable, weighted-average remaining contractual life (Year)", "documentation": "Weighted average remaining contractual term for equity instruments other than options and options that are exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "nby_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstanding", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "nby_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstanding", "periodStartLabel": "Outstanding awards (in shares)", "periodEndLabel": "Outstanding awards (in shares)", "documentation": "The number of equity-based payment instruments, including stock (or unit) options, outstanding during the reporting period." } } }, "auth_ref": [] }, "nby_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "nby_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstandingWeightedAverageExercisePrice", "periodStartLabel": "Outstanding, weighted-average exercise price (in dollars per share)", "periodEndLabel": "Outstanding, weighted-average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan or equity instruments other than options." } } }, "auth_ref": [] }, "nby_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Vested and expected to vest, aggregate intrinsic value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest equity instruments other than options and options outstanding." } } }, "auth_ref": [] }, "nby_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Vested and expected to vest (in shares)", "documentation": "As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options and equity instruments other than options outstanding can be converted under the option plan." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r441", "r442", "r443", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r465", "r466", "r467", "r468", "r469" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Restricted stock units granted, weighted-average exercise price (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r449" ] }, "nby_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Restricted stock units vested, weighted-average exercise price (in dollars per share)", "documentation": "Weighted average per share amount of options vested in period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r437", "r444", "r463", "r464", "r465", "r466", "r469", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487" ] }, "us-gaap_ShareBasedPaymentArrangementEmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedPaymentArrangementEmployeeMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Employee [Member]", "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires." } } }, "auth_ref": [ "r439", "r441", "r442", "r443", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r465", "r466", "r467", "r468", "r469" ] }, "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedPaymentArrangementNonemployeeMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonemployee [Member]", "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires." } } }, "auth_ref": [ "r438", "r441", "r442", "r443", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r465", "r466", "r467", "r468", "r469" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharePrice", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharePrice", "terseLabel": "Share Price (in dollars per share)", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r886" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Outstanding, weighted-average remaining contractual life (Year)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r123" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [ "r1222" ] }, "nby_ShareholderOfMoreThan10PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "ShareholderOfMoreThan10PercentMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Shareholder of More Than 10% [Member]", "documentation": "Represents the shareholder of more than 10%." } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharesIssuedPricePerShare", "terseLabel": "Shares Issued, Price Per Share (in dollars per share)", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharesOutstanding", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharesOutstanding", "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r197", "r198" ] }, "nby_SouthCarolinaDepartmentOfRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "SouthCarolinaDepartmentOfRevenueMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-income-tax-paid-net-of-refunds-details" ], "lang": { "en-us": { "role": { "label": "South Carolina Department of Revenue [Member]", "documentation": "Represents the South Carolina Department of Revenue." } } }, "auth_ref": [] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-net-operating-loss-and-tax-credit-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "State and Local Jurisdiction [Member]", "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax." } } }, "auth_ref": [ "r498" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets", "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows4D8E0948-3376-4886-A031-7AF56055462E", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r145", "r170", "r171", "r172", "r199", "r202", "r234", "r235", "r238", "r240", "r246", "r247", "r270", "r308", "r310", "r311", "r312", "r315", "r316", "r350", "r351", "r353", "r354", "r356", "r360", "r363", "r364", "r368", "r371", "r378", "r634", "r733", "r734", "r735", "r736", "r742", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r766", "r786", "r808", "r825", "r826", "r827", "r828", "r829", "r997", "r1076", "r1078", "r1089" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r12", "r85", "r89", "r90", "r148", "r155", "r156", "r179", "r180", "r181", "r210", "r211", "r212", "r215", "r224", "r227", "r229", "r245", "r271", "r274", "r288", "r348", "r380", "r477", "r521", "r522", "r536", "r537", "r538", "r541", "r548", "r549", "r582", "r584", "r585", "r586", "r587", "r589", "r590", "r591", "r592", "r593", "r604", "r635", "r636", "r637", "r638", "r639", "r640", "r644", "r646", "r664", "r702", "r716", "r717", "r718", "r742", "r808" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementLineItems", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets", "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows4D8E0948-3376-4886-A031-7AF56055462E", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flowsA866F64D-8A89-45C0-926D-49809D27BFD0", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity-parentheticals", "http://www.novabaypharma.com/20251231/role/statement-note-1-organization", "http://www.novabaypharma.com/20251231/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-options-outstanding-details", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-tables", "http://www.novabaypharma.com/20251231/role/statement-note-12-employee-benefit-plan", "http://www.novabaypharma.com/20251231/role/statement-note-12-employee-benefit-plan-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-tables", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-tables", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-tables", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations-disposal-groups-including-discontinued-operations-details", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations-tables", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-federal-and-state-income-tax-provisions-details", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-loss-before-provision-for-income-taxes-details", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-schedule-of-income-tax-paid-net-of-refunds-details", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-net-operating-loss-and-tax-credit-carryforwards-details", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-tables", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-unrecognized-tax-benefit-details", "http://www.novabaypharma.com/20251231/role/statement-note-18-related-party-transactions", "http://www.novabaypharma.com/20251231/role/statement-note-18-related-party-transactions-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-cash-cash-equivalents-restricted-cash-and-restricted-cash-equivalents-details", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-earnings-per-share-basic-and-diluted-details", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-tables", "http://www.novabaypharma.com/20251231/role/statement-note-4-prepaid-expenses-and-other-current-assets", "http://www.novabaypharma.com/20251231/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details", "http://www.novabaypharma.com/20251231/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables", "http://www.novabaypharma.com/20251231/role/statement-note-5-accrued-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-5-accrued-liabilities-summary-of-accrued-liabilities-details", "http://www.novabaypharma.com/20251231/role/statement-note-5-accrued-liabilities-tables", "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies", "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-lease-expense-details", "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-schedule-of-future-lease-payments-details", "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-tables", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-tables", "http://www.novabaypharma.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r210", "r211", "r212", "r245", "r350", "r351", "r353", "r356", "r646", "r682", "r731", "r743", "r754", "r758", "r759", "r760", "r761", "r762", "r763", "r766", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r779", "r780", "r781", "r782", "r783", "r787", "r788", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r808", "r852", "r853", "r951", "r1318" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "StatementScenarioAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-1-organization", "http://www.novabaypharma.com/20251231/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r160", "r162", "r230", "r436", "r998", "r999" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementTable", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets", "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows4D8E0948-3376-4886-A031-7AF56055462E", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flowsA866F64D-8A89-45C0-926D-49809D27BFD0", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity-parentheticals" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r210", "r211", "r212", "r245", "r268", "r350", "r351", "r353", "r356", "r646", "r682", "r731", "r743", "r754", "r758", "r759", "r760", "r761", "r762", "r763", "r766", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r779", "r780", "r781", "r782", "r783", "r787", "r788", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r808", "r852", "r853", "r951", "r1318" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity" ], "lang": { "en-us": { "role": { "label": "Conversion of Preferred Stock to common stock (in shares)", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r12", "r39", "r85", "r89", "r120", "r334" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Issuance of Preferred Stock (in shares)", "terseLabel": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r12", "r84", "r85", "r120", "r733", "r808", "r826" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity" ], "lang": { "en-us": { "role": { "label": "Vesting of director restricted stock awards (in shares)", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r12", "r84", "r85", "r120" ] }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity" ], "lang": { "en-us": { "role": { "label": "Shares issued for 35:1 reverse stock split due to rounding feature (in shares)", "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split." } } }, "auth_ref": [ "r12" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r12", "r84", "r85", "r120", "r450" ] }, "nby_StockIssuedDuringPeriodSharesWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "StockIssuedDuringPeriodSharesWarrantsExercised", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_StockIssuedDuringPeriodSharesWarrantsExercised", "terseLabel": "Stock Issued During Period, Shares, Warrants Exercised (in shares)", "documentation": "The number of shares of stock issued during period due to warrants exercised." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity" ], "lang": { "en-us": { "role": { "label": "Conversion of Preferred Stock to common stock", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r12", "r85", "r89", "r90", "r120" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows4D8E0948-3376-4886-A031-7AF56055462E", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Issuance of Preferred Stock", "terseLabel": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r12", "r84", "r85", "r120", "r742", "r808", "r826", "r957" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity" ], "lang": { "en-us": { "role": { "label": "Vesting of director restricted stock awards", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r12", "r120" ] }, "nby_StockIssuedDuringPeriodValueReverseStockSplits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "StockIssuedDuringPeriodValueReverseStockSplits", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity" ], "lang": { "en-us": { "role": { "label": "Shares issued for 35:1 reverse stock split due to rounding feature", "documentation": "Represents the amount as a result of a reduction in the number of shares during the period as a result of a reverse stock split." } } }, "auth_ref": [] }, "nby_StockIssuedInConnectionWithExerciseOfWarrantsShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "StockIssuedInConnectionWithExerciseOfWarrantsShares", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "Stock Issued In Connection with Exercise of Warrants, Shares (in shares)", "terseLabel": "Stock Issued In Connection with Exercise of Warrants, Shares", "documentation": "Stock issued in connection with warrants exercise." } } }, "auth_ref": [] }, "nby_StockIssuedInConnectionWithExerciseOfWarrantsValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "StockIssuedInConnectionWithExerciseOfWarrantsValue", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "Stock Issued In Connection with Exercise of Warrants, Value", "terseLabel": "Stock Issued In Connection with Exercise of Warrants, Value", "documentation": "Value of stock issued as a result of warrants exercise.." } } }, "auth_ref": [] }, "us-gaap_StockOptionPlanExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockOptionPlanExpense", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockOptionPlanExpense", "terseLabel": "Stock-based compensation expense related to employee and director stock awards", "documentation": "Amount of noncash expense for option under share-based payment arrangement." } } }, "auth_ref": [ "r8" ] }, "us-gaap_StockRedeemedOrCalledDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockRedeemedOrCalledDuringPeriodShares", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockRedeemedOrCalledDuringPeriodShares", "terseLabel": "Stock Redeemed or Called During Period, Shares", "documentation": "Number of stock bought back by the entity at the exercise price or redemption price." } } }, "auth_ref": [ "r12" ] }, "us-gaap_StockRedeemedOrCalledDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockRedeemedOrCalledDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockRedeemedOrCalledDuringPeriodValue", "terseLabel": "Stock Redeemed or Called During Period, Value", "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price." } } }, "auth_ref": [ "r12" ] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockRepurchasedDuringPeriodShares", "negatedLabel": "Redemption of Series F Preferred Stock (in shares)", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r12", "r84", "r85", "r120", "r736", "r808", "r828" ] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockRepurchasedDuringPeriodValue", "negatedLabel": "Redemption of Series F Preferred Stock", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r12", "r84", "r85", "r120", "r742", "r808", "r828", "r957" ] }, "nby_StockholderApprovalMay282024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "StockholderApprovalMay282024Member", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Stockholder Approval May 28 2024 [Member]", "documentation": "Represents Stockholder Approval on May 28, 2024." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquity", "totalLabel": "Total stockholders\u2019 (deficit)", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r85", "r89", "r90", "r106", "r768", "r784", "r809", "r810", "r940", "r958", "r1074", "r1078", "r1079", "r1101", "r1263", "r1319" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 deficit:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit" ], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r116", "r362", "r364", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r377", "r380", "r578", "r595", "r811", "r813", "r830" ] }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity-parentheticals", "http://www.novabaypharma.com/20251231/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1", "terseLabel": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": [ "r121" ] }, "nby_StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note, Warrants or Rights Disclosure [Text Block]", "documentation": "The entire disclosure of warrants or rights." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-1-organization", "http://www.novabaypharma.com/20251231/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r641", "r673" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventTable", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r641", "r673" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-1-organization", "http://www.novabaypharma.com/20251231/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r641", "r673" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-1-organization", "http://www.novabaypharma.com/20251231/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r641", "r673" ] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r672", "r674" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "http://www.novabaypharma.com/20251231/role/statement-note-1-organization", "http://www.novabaypharma.com/20251231/role/statement-note-1-organization-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "nby_SummaryOfDisposalGroupsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "SummaryOfDisposalGroupsMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations-tables" ], "lang": { "en-us": { "role": { "label": "Summary of Disposal Groups [Member]", "documentation": "Represents a summary of disposal groups." } } }, "auth_ref": [] }, "nby_SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Summary of Operating Loss Carryforwards and Tax Credit Carryforwards [Table Text Block]", "documentation": "Tabular disclosure of operating loss carryforwards and tax credit carryforwards." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flowsA866F64D-8A89-45C0-926D-49809D27BFD0" ], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "auth_ref": [] }, "nby_TLFBioInnovationWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "TLFBioInnovationWarrantsMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details" ], "lang": { "en-us": { "role": { "label": "TLF Bio Innovation Warrants [Member]", "documentation": "Represents TLF Bio Innovation warrants." } } }, "auth_ref": [] }, "us-gaap_TableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TableTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-tables", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-tables", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-tables", "http://www.novabaypharma.com/20251231/role/statement-note-15-dermadoctor-divestiture-tables", "http://www.novabaypharma.com/20251231/role/statement-note-16-summary-of-discontinued-operations-tables", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-tables", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-tables", "http://www.novabaypharma.com/20251231/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables", "http://www.novabaypharma.com/20251231/role/statement-note-5-accrued-liabilities-tables", "http://www.novabaypharma.com/20251231/role/statement-note-6-commitments-and-contingencies-tables", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-tables" ], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "auth_ref": [] }, "us-gaap_TangibleAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TangibleAssetImpairmentCharges", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_TangibleAssetImpairmentCharges", "terseLabel": "Tangible Asset Impairment Charges", "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value." } } }, "auth_ref": [ "r57", "r109" ] }, "us-gaap_TaxCreditCarryforwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TaxCreditCarryforwardAmount", "crdr": "debit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-net-operating-loss-and-tax-credit-carryforwards-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Tax credits", "label": "us-gaap_TaxCreditCarryforwardAmount", "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r518" ] }, "us-gaap_TaxPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TaxPeriodAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-net-operating-loss-and-tax-credit-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Tax Period [Axis]", "documentation": "Information by period subject to enacted tax law." } } }, "auth_ref": [ "r1227" ] }, "us-gaap_TaxPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TaxPeriodDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes", "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-summary-of-net-operating-loss-and-tax-credit-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Tax Period [Domain]", "documentation": "Identified tax period." } } }, "auth_ref": [ "r1227" ] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TaxesPayableCurrent", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-5-accrued-liabilities-summary-of-accrued-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Income taxes", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r72", "r73" ] }, "us-gaap_TemporaryEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TemporaryEquityAbstract", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Mezzanine (temporary) equity:" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TemporaryEquityCarryingAmountAttributableToParent", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Preferred stock, $0.01 par value; 5,000 shares authorized; Series F Preferred Stock; 1,347 and 0 shares issued and outstanding at December 31, 2025 and 2024, respectively", "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r308", "r310", "r311", "r312", "r315", "r316", "r350", "r351", "r353", "r357", "r488", "r490", "r698" ] }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TemporaryEquityParOrStatedValuePerShare", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Par or Stated Value Per Share (in dollars per share)", "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable." } } }, "auth_ref": [ "r17" ] }, "us-gaap_TemporaryEquitySharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TemporaryEquitySharesAuthorized", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Shares Authorized (in shares)", "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r83", "r353" ] }, "us-gaap_TemporaryEquitySharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TemporaryEquitySharesIssued", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Shares Issued (in shares)", "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r83", "r353" ] }, "us-gaap_TemporaryEquitySharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TemporaryEquitySharesOutstanding", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Shares Outstanding (in shares)", "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r83", "r353" ] }, "nby_The2007OmnibusIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "The2007OmnibusIncentivePlanMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "The 2007 Omnibus Incentive Plan [Member]", "documentation": "Represents the 2007 Omnibus Incentive Plan." } } }, "auth_ref": [] }, "nby_The2017OmnibusIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "The2017OmnibusIncentivePlanMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "The 2017 Omnibus Incentive Plan [Member]", "documentation": "Represents the 2017 Omnibus Incentive Plan." } } }, "auth_ref": [] }, "nby_The2021PrivatePlacementProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "The2021PrivatePlacementProgramMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit", "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "The 2021 Private Placement Program [Member]", "documentation": "Represents the 2021 private placement program." } } }, "auth_ref": [] }, "nby_The2022WarrantRepriceTransactionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "The2022WarrantRepriceTransactionMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "The 2022 Warrant Reprice Transaction [Member]", "documentation": "Represents the 2022 warrant reprice transaction." } } }, "auth_ref": [] }, "nby_The2024PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "The2024PublicOfferingMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "The 2024 Public Offering [Member]", "documentation": "Represents the 2024 Public Offering" } } }, "auth_ref": [] }, "nby_The2024WarrantRepriceTransactionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "The2024WarrantRepriceTransactionMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "The 2024 Warrant Reprice Transaction [Member]", "documentation": "Represents the 2024 warrant reprice transaction." } } }, "auth_ref": [] }, "nby_The401kPlanContributionLevelOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "The401kPlanContributionLevelOneMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-12-employee-benefit-plan", "http://www.novabaypharma.com/20251231/role/statement-note-12-employee-benefit-plan-details-textual" ], "lang": { "en-us": { "role": { "label": "The 401K Plan Contribution Level One [Member]", "documentation": "The 401K Plan Contribution Level One." } } }, "auth_ref": [] }, "nby_The401kPlanContributionLevelTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "The401kPlanContributionLevelTwoMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-12-employee-benefit-plan", "http://www.novabaypharma.com/20251231/role/statement-note-12-employee-benefit-plan-details-textual" ], "lang": { "en-us": { "role": { "label": "The 401K Plan Contribution Level Two [Member]", "documentation": "Represents The 401k Plan Contribution Level Two." } } }, "auth_ref": [] }, "nby_TheAmendedNovember2022A1AndA2WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "TheAmendedNovember2022A1AndA2WarrantsMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "The Amended November 2022 A-1 and A-2 Warrants [Member]", "documentation": "Represents the amended November A warrants." } } }, "auth_ref": [] }, "nby_TheDecember2023WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "TheDecember2023WarrantsMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details" ], "lang": { "en-us": { "role": { "label": "The December 2023 Warrants [Member]", "documentation": "Represents December 2023 Warrants." } } }, "auth_ref": [] }, "nby_TheJanuary2026WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "TheJanuary2026WarrantsMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "The January 2026 Warrants [Member]", "documentation": "Represents the January 2026 warrants." } } }, "auth_ref": [] }, "nby_TheJuly2020WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "TheJuly2020WarrantsMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details" ], "lang": { "en-us": { "role": { "label": "The July 2020 Warrants [Member]", "documentation": "Represents the July 2020 warrants." } } }, "auth_ref": [] }, "nby_TheJuly2024PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "TheJuly2024PreFundedWarrantsMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details" ], "lang": { "en-us": { "role": { "label": "The July 2024 Pre-Funded Warrants [Member]", "documentation": "Represents the July 2024 pre-funded warrants." } } }, "auth_ref": [] }, "nby_TheJuly2024SeriesF1AndF3WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "TheJuly2024SeriesF1AndF3WarrantsMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "The July 2024 Series F-1 and F-3 Warrants [Member]", "documentation": "Represents the July 2024 series F-1 and F-3 warrants." } } }, "auth_ref": [] }, "nby_TheJuly2024SeriesF1WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "TheJuly2024SeriesF1WarrantsMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details" ], "lang": { "en-us": { "role": { "label": "The July 2024 Series F-1 Warrants [Member]", "documentation": "Related to warrants." } } }, "auth_ref": [] }, "nby_TheJuly2024SeriesF2WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "TheJuly2024SeriesF2WarrantsMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details" ], "lang": { "en-us": { "role": { "label": "The July 2024 Series F-2 Warrants [Member]", "documentation": "Related to warrants." } } }, "auth_ref": [] }, "nby_TheJuly2024SeriesF3WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "TheJuly2024SeriesF3WarrantsMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details" ], "lang": { "en-us": { "role": { "label": "The July 2024 Series F-3 Warrants [Member]", "documentation": "Related to warrants." } } }, "auth_ref": [] }, "nby_TheJuly2024WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "TheJuly2024WarrantsMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "The July 2024 Warrants [Member]", "documentation": "Related to warrants." } } }, "auth_ref": [] }, "nby_TheMay2023B1WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "TheMay2023B1WarrantsMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "The May 2023 B-1 Warrants [Member]", "documentation": "Represents May 2023 B-1 Warrants." } } }, "auth_ref": [] }, "nby_TheMay2023B2WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "TheMay2023B2WarrantsMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "The May 2023 B-2 Warrants [Member]", "documentation": "Represents May 2023 B-2 Warrants." } } }, "auth_ref": [] }, "nby_TheNovember2021WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "TheNovember2021WarrantsMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details" ], "lang": { "en-us": { "role": { "label": "The November 2021 Warrants [Member]", "documentation": "Represents the November 2021 Warrants." } } }, "auth_ref": [] }, "nby_TheNovember2022A1AndA2WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "TheNovember2022A1AndA2WarrantsMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "The November 2022 A-1 and A-2 Warrants [Member]", "documentation": "Represents the November 2022 warrants." } } }, "auth_ref": [] }, "nby_TheNovember2022A1WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "TheNovember2022A1WarrantsMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details" ], "lang": { "en-us": { "role": { "label": "The November 2022 A-1 Warrants [Member]", "documentation": "Represents November 2022 A-1 Warrants." } } }, "auth_ref": [] }, "nby_TheNovember2022A2WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "TheNovember2022A2WarrantsMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "The November 2022 A-2 Warrants [Member]", "documentation": "Represents November 2022 A-2 Warrants." } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": [ "r1099", "r1274" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-stockholders-deficit-equity", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation", "http://www.novabaypharma.com/20251231/role/statement-note-11-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r982" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "nby_TrancheOneBridgeLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "TrancheOneBridgeLoanMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan", "http://www.novabaypharma.com/20251231/role/statement-note-13-avenova-asset-divestiture-and-bridge-loan-details-textual" ], "lang": { "en-us": { "role": { "label": "Tranche One, Bridge Loan [Member]", "documentation": "The first tranche for the bridge loan." } } }, "auth_ref": [] }, "nby_USDSTokensMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "USDSTokensMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "USDS Tokens [Member]", "documentation": "Represents USDS tokens." } } }, "auth_ref": [] }, "nby_USDTAndUSDSTokensMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "USDTAndUSDSTokensMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "USDT and USDS Tokens [Member]", "documentation": "Represents USDT and USDS tokens." } } }, "auth_ref": [] }, "nby_USDTTokensMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "USDTTokensMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "USDT Tokens [Member]", "documentation": "Represents USDT tokens." } } }, "auth_ref": [] }, "nby_UnderwriterFrom2024PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "UnderwriterFrom2024PublicOfferingMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities", "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "Underwriter From 2024 Public Offering [Member]", "documentation": "Represents the underwriter for the 2024 Public Offering." } } }, "auth_ref": [] }, "nby_UnderwrittenRegisteredDirectOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "UnderwrittenRegisteredDirectOfferingMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Underwritten Registered Direct Offering [Member]", "documentation": "Represents the underwritten registered direct offering." } } }, "auth_ref": [] }, "us-gaap_UnrealizedGainLossOnDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UnrealizedGainLossOnDerivatives", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_UnrealizedGainLossOnDerivatives", "terseLabel": "Unrealized Gain (Loss) on Derivatives", "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period." } } }, "auth_ref": [ "r8", "r802", "r803", "r804", "r805", "r821" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-unrecognized-tax-benefit-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_UnrecognizedTaxBenefits", "periodStartLabel": "Unrecognized benefit - beginning of period", "periodEndLabel": "Unrecognized benefit - end of period", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r493", "r507", "r888" ] }, "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-unrecognized-tax-benefit-details" ], "lang": { "en-us": { "role": { "label": "Change during the period", "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns." } } }, "auth_ref": [ "r1228" ] }, "nby_UnsecuredConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "UnsecuredConvertibleNotesMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events", "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements", "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Unsecured Convertible Notes [Member]", "documentation": "Relating Unsecured Convertible Notes." } } }, "auth_ref": [] }, "us-gaap_UnsecuredDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UnsecuredDebtCurrent", "crdr": "credit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-balance-sheets", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Unsecured Convertible Notes, net of discounts", "terseLabel": "Unsecured Debt, Current", "documentation": "Carrying value as of the balance sheet date of the portion of long-term, uncollateralized debt obligations due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r72", "r129" ] }, "us-gaap_UnsecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UnsecuredDebtMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes", "http://www.novabaypharma.com/20251231/role/statement-note-8-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Unsecured Debt [Member]", "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets." } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UseOfEstimates", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r140", "r141", "r248", "r249", "r250", "r251", "r686", "r688", "r856" ] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-17-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount", "terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r510" ] }, "nby_VotingEquivalent": { "xbrltype": "pureItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "VotingEquivalent", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-10-stockholders-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_VotingEquivalent", "terseLabel": "Voting Equivalent", "documentation": "Represents the voting equivalent." } } }, "auth_ref": [] }, "us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount", "crdr": "debit", "calculation": { "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-earnings-per-share-basic-and-diluted-details" ], "lang": { "en-us": { "role": { "label": "Less: Increase to accumulated deficit due to adjustment to common stock warrants exercise price", "negatedLabel": "Less: Increase to accumulated deficit due to adjustment to common stock warrant exercise price", "documentation": "Amount of decrease in net income available to common shareholder for down round feature triggered for warrant classified as equity." } } }, "auth_ref": [ "r233", "r240" ] }, "nby_WarrantLiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "WarrantLiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrant liability", "label": "nby_WarrantLiabilitiesFairValueDisclosure", "documentation": "The fair value of warrant obligations." } } }, "auth_ref": [] }, "nby_WarrantLiabilitiesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "WarrantLiabilitiesPolicyTextBlock", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Warrant Liabilities [Policy Text Block]", "documentation": "The disclosure of accounting policy for warrant liabilities." } } }, "auth_ref": [] }, "nby_WarrantLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "WarrantLiabilityMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows4D8E0948-3376-4886-A031-7AF56055462E", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities", "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Warrant Liability [Member]", "documentation": "Represents information about warrant liability." } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WarrantMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.novabaypharma.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r948", "r949", "r952", "r953", "r954", "r955" ] }, "nby_WarrantsAndPrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "WarrantsAndPrefundedWarrantsMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Warrants and Pre-funded Warrants [Member]", "documentation": "Represents warrants and pre-funded warrants." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_WarrantsAndRightsOutstanding", "periodStartLabel": "Warrant liabilities", "periodEndLabel": "Warrant liabilities", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [ "r1246", "r1247", "r1248" ] }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WarrantsAndRightsOutstandingMaturityDate", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-9-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details" ], "lang": { "en-us": { "role": { "label": "Expiration Date", "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format." } } }, "auth_ref": [ "r1246", "r1247", "r1248" ] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": [ "r1246", "r1247", "r1248" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-7-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_WarrantsAndRightsOutstandingTerm", "terseLabel": "Warrants and Rights Outstanding, Term (Year)", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1246", "r1247", "r1248" ] }, "nby_WarrantsExercisableAtNinthMonthsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "WarrantsExercisableAtNinthMonthsPercentage", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_WarrantsExercisableAtNinthMonthsPercentage", "terseLabel": "Warrants Exercisable at Ninth Months, Percentage", "documentation": "The percentage of warrants exercisable nine months after execution." } } }, "auth_ref": [] }, "nby_WarrantsExercisableAtSixMonthsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "WarrantsExercisableAtSixMonthsPercentage", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_WarrantsExercisableAtSixMonthsPercentage", "terseLabel": "Warrants Exercisable at Six Months, Percentage", "documentation": "The percentage of warrants exercisable six months after execution." } } }, "auth_ref": [] }, "nby_WarrantsExercisableAtTwelveMonthsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "WarrantsExercisableAtTwelveMonthsPercentage", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-19-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "nby_WarrantsExercisableAtTwelveMonthsPercentage", "terseLabel": "Warrants Exercisable at Twelve Months, Percentage", "documentation": "The percentage of warrants exercisable twelve months after execution." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Basic (and diluted for net loss) (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r231", "r240" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding:" } } }, "auth_ref": [] }, "nby_WoundCareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "WoundCareMember", "presentation": [ "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-details-textual", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-heldforsale-details", "http://www.novabaypharma.com/20251231/role/statement-note-14-phaseone-divestiture-tables" ], "lang": { "en-us": { "role": { "label": "Wound Care [Member]", "documentation": "Represents wound care." } } }, "auth_ref": [] }, "nby_statement-statement-note-11-stockbased-compensation-stock-options-outstanding-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-11-stockbased-compensation-stock-options-outstanding-details", "lang": { "en-us": { "role": { "label": "Note 11 - Stock-based Compensation - Stock Options Outstanding (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-11-stockbased-compensation-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-11-stockbased-compensation-tables", "lang": { "en-us": { "role": { "label": "Note 11 - Stock-based Compensation" } } }, "auth_ref": [] }, "nby_statement-statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-13-avenova-asset-divestiture-and-bridge-loan-discontinued-operations-details", "lang": { "en-us": { "role": { "label": "Note 13 - Avenova Asset Divestiture and Bridge Loan - Discontinued Operations (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-13-avenova-asset-divestiture-and-bridge-loan-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-13-avenova-asset-divestiture-and-bridge-loan-tables", "lang": { "en-us": { "role": { "label": "Note 13 - Avenova Asset Divestiture and Bridge Loan" } } }, "auth_ref": [] }, "nby_statement-statement-note-14-phaseone-divestiture-heldforsale-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-14-phaseone-divestiture-heldforsale-details", "lang": { "en-us": { "role": { "label": "Note 14 - Phaseone Divestiture - Held-for-sale (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-14-phaseone-divestiture-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-14-phaseone-divestiture-tables", "lang": { "en-us": { "role": { "label": "Note 14 - Phaseone Divestiture" } } }, "auth_ref": [] }, "nby_statement-statement-note-15-dermadoctor-divestiture-discontinued-operations-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-15-dermadoctor-divestiture-discontinued-operations-details", "lang": { "en-us": { "role": { "label": "Note 15 - Dermadoctor Divestiture - Discontinued Operations (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-15-dermadoctor-divestiture-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-15-dermadoctor-divestiture-tables", "lang": { "en-us": { "role": { "label": "Note 15 - Dermadoctor Divestiture" } } }, "auth_ref": [] }, "nby_statement-statement-note-16-summary-of-discontinued-operations-disposal-groups-including-discontinued-operations-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-16-summary-of-discontinued-operations-disposal-groups-including-discontinued-operations-details", "lang": { "en-us": { "role": { "label": "Note 16 - Summary of Discontinued Operations - Disposal Groups, Including Discontinued Operations (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-16-summary-of-discontinued-operations-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-16-summary-of-discontinued-operations-tables", "lang": { "en-us": { "role": { "label": "Note 16 - Summary of Discontinued Operations" } } }, "auth_ref": [] }, "nby_statement-statement-note-17-income-taxes-federal-and-state-income-tax-provisions-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-17-income-taxes-federal-and-state-income-tax-provisions-details", "lang": { "en-us": { "role": { "label": "Note 17 - Income Taxes - Federal and State Income Tax Provisions (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-17-income-taxes-loss-before-provision-for-income-taxes-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-17-income-taxes-loss-before-provision-for-income-taxes-details", "lang": { "en-us": { "role": { "label": "Note 17 - Income Taxes - Loss Before Provision for Income Taxes (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-17-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details", "lang": { "en-us": { "role": { "label": "Note 17 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-17-income-taxes-schedule-of-income-tax-paid-net-of-refunds-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-17-income-taxes-schedule-of-income-tax-paid-net-of-refunds-details", "lang": { "en-us": { "role": { "label": "Note 17 - Income Taxes - Schedule of Income Tax Paid, Net of Refunds (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-17-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details", "lang": { "en-us": { "role": { "label": "Note 17 - Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-17-income-taxes-summary-of-net-operating-loss-and-tax-credit-carryforwards-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-17-income-taxes-summary-of-net-operating-loss-and-tax-credit-carryforwards-details", "lang": { "en-us": { "role": { "label": "Note 17 - Income Taxes - Summary of Net operating Loss and Tax Credit Carryforwards (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-17-income-taxes-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-17-income-taxes-tables", "lang": { "en-us": { "role": { "label": "Note 17 - Income Taxes" } } }, "auth_ref": [] }, "nby_statement-statement-note-17-income-taxes-unrecognized-tax-benefit-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-17-income-taxes-unrecognized-tax-benefit-details", "lang": { "en-us": { "role": { "label": "Note 17 - Income Taxes - Unrecognized Tax Benefit (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details", "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-cash-cash-equivalents-restricted-cash-and-restricted-cash-equivalents-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-cash-cash-equivalents-restricted-cash-and-restricted-cash-equivalents-details", "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-earnings-per-share-basic-and-diluted-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-earnings-per-share-basic-and-diluted-details", "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Schedule of Earnings Per Share, Basic and Diluted (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-2-summary-of-significant-accounting-policies-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-tables", "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "nby_statement-statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details", "lang": { "en-us": { "role": { "label": "Note 3 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-3-fair-value-measurements-fair-value-valuation-assumptions-details", "lang": { "en-us": { "role": { "label": "Note 3 - Fair Value Measurements - Fair Value Valuation Assumptions (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-3-fair-value-measurements-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-3-fair-value-measurements-tables", "lang": { "en-us": { "role": { "label": "Note 3 - Fair Value Measurements" } } }, "auth_ref": [] }, "nby_statement-statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details", "lang": { "en-us": { "role": { "label": "Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-4-prepaid-expenses-and-other-current-assets-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-4-prepaid-expenses-and-other-current-assets-tables", "lang": { "en-us": { "role": { "label": "Note 4 - Prepaid Expenses and Other Current Assets" } } }, "auth_ref": [] }, "nby_statement-statement-note-5-accrued-liabilities-summary-of-accrued-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-5-accrued-liabilities-summary-of-accrued-liabilities-details", "lang": { "en-us": { "role": { "label": "Note 5 - Accrued Liabilities - Summary of Accrued Liabilities (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-5-accrued-liabilities-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-5-accrued-liabilities-tables", "lang": { "en-us": { "role": { "label": "Note 5 - Accrued Liabilities" } } }, "auth_ref": [] }, "nby_statement-statement-note-6-commitments-and-contingencies-lease-expense-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-6-commitments-and-contingencies-lease-expense-details", "lang": { "en-us": { "role": { "label": "Note 6 - Commitments and Contingencies - Lease Expense (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-6-commitments-and-contingencies-schedule-of-future-lease-payments-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-6-commitments-and-contingencies-schedule-of-future-lease-payments-details", "lang": { "en-us": { "role": { "label": "Note 6 - Commitments and Contingencies - Schedule of Future Lease Payments (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-6-commitments-and-contingencies-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-6-commitments-and-contingencies-tables", "lang": { "en-us": { "role": { "label": "Note 6 - Commitments and Contingencies" } } }, "auth_ref": [] }, "nby_statement-statement-note-9-common-stock-warrants-and-warrant-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-9-common-stock-warrants-and-warrant-liabilities-details", "lang": { "en-us": { "role": { "label": "Note 9 - Common Stock Warrants and Warrant Liabilities (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-9-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-9-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details", "lang": { "en-us": { "role": { "label": "Note 9 - Common Stock Warrants and Warrant Liabilities - Schedule of Stockholders' Equity Note, Warrants or Rights (Details)" } } }, "auth_ref": [] }, "nby_statement-statement-note-9-common-stock-warrants-and-warrant-liabilities-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-note-9-common-stock-warrants-and-warrant-liabilities-tables", "lang": { "en-us": { "role": { "label": "Note 9 - Common Stock Warrants and Warrant Liabilities" } } }, "auth_ref": [] }, "nby_statement-statement-significant-accounting-policies-policies": { "xbrltype": "stringItemType", "nsuri": "http://www.novabaypharma.com/20251231", "localname": "statement-statement-significant-accounting-policies-policies", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-11" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480781/205-20-S99-3" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-11" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-18" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-20/tableOfContent" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3B" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-4" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-9" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "470", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SAB Topic 1.B.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-23" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-12B" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476163/350-60-45-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-3" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.FF.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476188/405-10-S99-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(24)(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/715/tableOfContent" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(j)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(j)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(j)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(j)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(m)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-7" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.E.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "S55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479772/718-30-S55-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CC", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "15", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480960/815-15-50-3" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482864/845-10-50-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482864/845-10-50-3" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-15" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4" }, "r854": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r858": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r859": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r860": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r861": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r862": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r863": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r864": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r865": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r866": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r867": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r868": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r869": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r870": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r871": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r872": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r873": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "64", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64" }, "r874": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r875": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r876": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r877": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r878": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r879": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r880": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r881": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r882": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r883": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r884": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r885": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r886": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r887": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r888": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r889": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r890": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8" }, "r891": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "43", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43" }, "r892": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47" }, "r893": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r894": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r895": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r896": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r897": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r898": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r899": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r900": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r901": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r902": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29" }, "r903": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29" }, "r904": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r905": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r906": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r907": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r908": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r909": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r910": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r911": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r912": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r913": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r914": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r915": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r916": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r917": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r918": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r919": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r920": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r921": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "181", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-181" }, "r922": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r923": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r924": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r925": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r926": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r927": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r928": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r929": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12" }, "r930": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r931": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r932": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4" }, "r933": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4" }, "r934": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4" }, "r935": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4" }, "r936": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-5" }, "r937": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6" }, "r938": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6" }, "r939": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6" }, "r940": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r941": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r942": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r943": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r944": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r945": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11" }, "r946": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14" }, "r947": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r948": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r949": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r950": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r951": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r952": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r953": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r954": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r955": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r956": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r957": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r958": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r959": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r960": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r961": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r962": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r963": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r964": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r965": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K" }, "r966": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r967": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r968": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r969": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r970": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "2" }, "r971": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "1" }, "r972": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2" }, "r973": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r974": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r975": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r976": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r977": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r978": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r979": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r980": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r981": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r982": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r983": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r984": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106" }, "r985": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1" }, "r986": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r987": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r988": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r989": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "2" }, "r990": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "1" }, "r991": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2" }, "r992": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r993": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r994": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r995": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r996": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r997": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r998": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r999": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "705", "Publisher": "FASB", "URI": "https://asc.fasb.org/705/tableOfContent" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(m)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(m)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(r)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(s)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(t)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(u)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "40", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476163/350-60-45-1" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-3" }, "r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-3" }, "r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-3" }, "r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-3" }, "r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-3" }, "r1111": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-4" }, "r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-6" }, "r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-6" }, "r1114": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r1116": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r1117": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405/tableOfContent" }, "r1118": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1119": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1120": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1121": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1122": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1123": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1124": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1125": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1126": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1127": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1128": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1129": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r1130": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1" }, "r1131": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r1132": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r1133": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1134": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1135": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1136": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1137": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1138": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1139": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1140": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1141": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1142": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1143": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1144": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1145": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1146": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1147": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1148": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1149": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1150": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1151": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1152": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1153": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1154": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1155": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1156": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1157": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1158": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1159": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1160": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1161": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1162": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1163": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1164": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1165": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1166": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1167": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1168": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1169": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1170": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1171": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1172": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1173": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1174": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1175": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1176": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1177": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1178": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1179": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1180": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r1181": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r1182": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r1183": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r1184": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1185": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1186": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1187": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1188": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1189": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1190": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1191": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1192": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1193": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8" }, "r1194": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r1195": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1196": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1197": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1198": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1199": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1200": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1201": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1202": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1203": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1204": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1205": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1206": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1207": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1208": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1209": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1210": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1211": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1212": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1213": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1214": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1215": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1216": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1217": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1218": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1219": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1220": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1221": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1222": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4" }, "r1223": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r1224": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1225": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1226": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r1227": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r1228": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r1229": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1230": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r1231": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r1232": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1233": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1234": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r1235": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r1236": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r1237": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A" }, "r1238": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r1239": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r1240": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r1241": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "15", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481116/815-15-25-1" }, "r1242": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1243": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1244": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1245": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1246": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1247": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1248": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1249": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1250": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1251": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1252": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1253": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1254": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1255": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1256": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1257": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1258": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r1259": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r1260": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r1261": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r1262": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1263": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1264": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1265": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r1266": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1267": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r1268": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1269": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479365/842-20-25-6" }, "r1270": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1271": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1272": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r1273": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r1274": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r1275": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1276": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1277": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1278": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1279": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1280": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1281": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1282": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1283": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r1284": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2" }, "r1285": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1286": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1287": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1288": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1289": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1290": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1291": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1292": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1293": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1294": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1295": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1296": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1297": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1298": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1299": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1300": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1301": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1302": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1303": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1304": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1305": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1306": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1307": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1308": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1309": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1310": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1311": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1312": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1313": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1314": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1315": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1316": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1317": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1318": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r1319": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1320": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } }